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1 Abstract 
The transcriptional programs triggered by p53 during tumor suppression and in response to DNA 
damage remain to be clarified. Using whole genome mapping of p53 binding and gene expression 
profiling, we investigated the transcriptional circuitry induced by p53 in suppressing cancer 
development and in response to genotoxic injury. We studied the progression of Myc-induced 
lymphomas in Eμ-myc transgenic mice, as well as the regression of these lymphomas following 
restoration of p53 function, by either pharmacological or genetic means. In parallel, we 
determined the p53-dependent transcriptional program in splenic cells from mice exposed to 
ionizing radiation. We thus expanded our understanding of the p53 response to oncogenic and 
genotoxic stress and identified a set of novel components of the p53 transcriptional program. 
Currently, we are testing the impact of these new p53 target genes on tumorigenesis using an 
RNA interference (RNAi)-based functional genetic screen. Altogether our data represent an 
extensive characterization of the p53-regulated network in response to different stimuli and will 
hopefully highlight new tumor suppressive mechanisms, paving the way for their therapeutic 
application. 
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2 Introduction 
The evolution of a normal cell towards a cancerous one involves stepwise accumulation of genetic 
and epigenetic changes that confer selective advantages to the transformed cells by disrupting 
the homeostatic mechanisms that govern normal cell proliferation. The alterations underlying 
tumorigenesis endow the neoplastic cells with several properties, including self-sufficiency of 
growth signals, evasion from cell cycle checkpoints and cell death, unlimited replicative potential, 
sustained angiogenesis, and the ability to invade and metastasize, among other tumorigenic 
features (1). 
Importantly, two classes of genes, oncogenes and tumor suppressor genes, fuel this malignant 
transformation, when aberrantly regulated. Oncogenes result from mutation or overexpression of 
a proto-oncogene causing its hyper-activation. The protein products of proto-oncogenes normally 
promote proliferation or provide other pro-survival signals to the cell. Disruption of their tight 
regulation leads to aberrant cell cycle progression and tumorigenesis. Classical examples of 
oncogenes include the Ras family of GTPases and the transcription factor Myc. Conversely, tumor 
suppressor genes normally regulate cell proliferation and ensure genome stability, inhibiting 
tumor development. Tumor suppressor genes, when inactivated, increase the selective growth 
advantage of the tumor cell. Examples are the retinoblastoma protein (Rb), which regulates cell 
cycle progression, and p53, which is a central hub in a molecular network controlling cell fate. 
Examination of these genes will continue to provide insights in the pathways that they regulate 
and guide to the development of effective cancer therapies. 
2.1 p53  
2.1.1 p53's discovery 
In 1979, six groups of investigators independently reported the discovery of a 53 kDa protein that 
was present in both human and mouse cells. In five of these studies, the protein was described to 
interact with the SV40 large T-antigen by co-precipitation using antibodies against the viral 
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protein (2,3,4,5,6). At the same time, Old and coworkers showed that animals immunized with 
chemically induced sarcomas and other transformed cells produced antisera to the same 53 kDa 
protein, suggesting that it was not of viral origin (7). Later, p53 was found to be expressed at high 
levels in a large variety of cancer cells, but not or at very low levels in normal cells (8). These initial 
evidences misled the scientists to believe that p53 was an oncogene with transforming 
capabilities. The turning point in p53 research occurred ten years after its discovery, in 1989, 
when in a search for a putative tumor suppressor gene on chromosome 17p, a small region that 
contained the TP53 gene was identified and shown to be mutated or deleted, as initially described 
in colorectal tumors and then in several other tumor types (9,10). It became clear that the 'wild-
type' TP53 genes used to demonstrate p53 supposed oncogenic functions were instead mutated 
clones (11). It took then short time to understand that p53 was a sequence-specific transcription 
factor that bound DNA as a tetramer (12,13,14,15,16) and that cancer associated mutations 
impaired its DNA binding activity (see below). 
2.1.2 TP53 is a tumor suppressor gene 
Further evidence that p53 is a bona fide tumor suppressor comes from patients with Li-Fraumeni 
syndrome (LFS), a rare familial cancer predisposition disorder associated with germline mutations 
of the TP53 gene with an estimated penetrance of 90-95% (17,18,19). Children and adults are 
affected by a wide array of cancers that occur predominantly at younger ages, developing a 
characteristic tumor spectrum including sarcomas, brain tumors, breast cancers and 
adrenocortical carcinomas (20).  
Definitive demonstration for p53's central role in tumor suppression comes from the generation 
of Trp53 knock-out mice that show a dramatic, and completely penetrant predisposition to cancer 
development (described in more details in section 2.3.1) (21,22,23).  
The importance of inactivating p53 during tumorigenesis is further confirmed by the observation 
that TP53 is arguably the most frequently altered gene in human cancers. TP53 mutations are 
reported to occur in almost every type of cancer at rates varying between 15% (for example, in 
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bone tumors) and close to 40% (for example, in ovarian, colorectal and head and neck cancers) 
(Fig. 1) (24).  
 
Fig. 1 - Frequency of TP53 somatic mutations in human cancers. 
Data retrieved from IARC TP53 Mutation Database, R17 release, November 2013 (24). 
The vast majority of TP53 mutations identified in sporadic cancers are missense mutations that 
occur in all exons of the TP53 gene, with a strong predominance in exons 4 - 9, which encode the 
DNA binding domain (DBD) of the protein, and in particular in six 'hot-spot' residues (Fig. 2). p53 
mutants can be classified as contact mutants, which harbor mutations in p53 residues that 
directly contact the DNA helix, such as R248Q and R273H, and structural mutants, which carry 
mutations that cause either local (e.g. G245S and R249S) or global conformational distortion (e.g. 
R175H and R282W) (25).  
 
Fig. 2 - Distribution of missense mutations along the 393 amino-acid sequence of p53. 
Source: Brosh R and Rotter V, Nature Reviews Cancer 2009, vol.9(10): 701-13 (25). 
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Ultimately, the majority of TP53 mutations abrogate p53's ability to bind DNA in a sequence-
specific manner and activate transcription of target genes, underlining how crucial p53 function as 
a transcription factor is for tumor suppression. p53 mutants can exert cancer-promoting effects 
by dominant-negative inactivation of the wild-type allele, through hetero-oligomerization of the 
mutant form with the wild-type form, as well as through the acquisition of gain-of-function (GOF) 
properties that actively promote tumor development increasing survival, proliferation, migration 
and invasion of the tumor cells. These GOF properties could explain why point mutations are 
more frequent than deletions in human cancers (25). 
2.1.3 Structure of the human p53 protein 
The p53 protein comprises multiple functional domains typical of transcription factors, including 
two transcriptional activation domains (TADs), a proline-rich domain (PRD), a sequence-specific 
DNA binding domain (DBD), a tetramerization domain (Tet), and C-terminal regulatory domains 
(Fig. 3) (26). The transactivation domains span residues 1-63 and are involved in the recruitment 
of histone modifying enzymes and coactivator complexes (27,28), and in the interaction with 
regulatory proteins, such as Mdm2 (29). C-terminal to the TADs, between residues 64-93, lies the 
proline-rich domain, which contains PXXP motifs, where P represents proline and X any amino 
acid. The main function of this domain seems to be structural, since knock-in mice carrying point 
mutations in the PXXP repeats appear largely normal (30), whereas complete deletion results in 
disruption of p53 tumor suppressive function (31). The DBD (residues 94-291) constitutes the core 
domain of the protein and is responsible for the sequence-specific binding to target DNA. As 
previously described, most cancer-associated mutations occur in this domain, underscoring the 
key importance of DNA binding for p53-mediated tumor suppression. The C-terminal part of p53 
contains the tetramerization domain (Tet) (residues 326-354), through which p53 monomers 
interact to oligomerize. Finally, at the extreme C-terminus between residues 355-393, there is a 
basic, lysine-rich domain, which contains phosphorylation and acetylation sites and undergoes 
extensive post-translational modification (PTM) that modulates p53 stabilization and sequence-
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specific DNA binding (32). The p53 gene is highly conserved across vertebrates, in particular the 
core DBD shows the highest inter-species sequence homology (33). 
 
 
 
Fig. 3 - p53 structure. 
Source: Joerger AC and Ferscht AR, Advances in Cancer Research 2007, vol.97: 1-23 (26). 
2.1.4 p53 functions as a stress sensor 
In non-transformed cells, p53 is a sensor for cellular stresses that regulates a large number of 
genes in response to a variety of cellular insults, including hyper-proliferative signals, DNA 
damage, hypoxia, nutrient deprivation, oxidative stress and many others (Fig. 4). In response to 
such stress signals, p53 is displaced from its negative regulators, thereby allowing its stabilization 
and activation through PTMs. Once activated, p53 binds its response elements and recruits 
diverse transcriptional coregulators such as histone modifying enzymes, chromatin remodelling 
factors, components of the mediator complex and of the transcription machinery to promote 
stress-specific and tissue-specific responses and suppress cellular transformation. As a safeguard 
against neoplasia, p53 drives apoptosis and senescence of irreparably damaged or malignant cells. 
Alternatively, p53 promotes protective, pro-survival responses such as transient cell cycle arrest 
and DNA repair in cells exposed to limited, reparable damage. Beyond triggering apoptosis and 
cell cycle arrest, p53 can regulate several additional cellular processes, including metabolic 
reprogramming, autophagy and signalling to the tumor microenvironment. These various 
responses rely primarily on p53 function as a transcription factor, but transcription-independent 
activities, such as direct activation of apoptosis at mitochondria, also contribute to the p53 
response (32,34,35). 
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Fig. 4 - p53 activating signals and responses in mediating tumor suppression. 
Source: Bieging KT, Mello SS, Attardi LD, Nature Reviews Cancer 2014, vol. 14(5): 359-70 (34). 
2.1.5 The Mdm2 family controls p53 protein levels and activity 
Inappropriate p53 activity can be detrimental for cell and organismal viability; therefore 
numerous mechanisms exist to keep p53 in check. Several E3 ubiquitin ligases - most prominently 
Mdm2 (29) but also others including Pirh2, Trim24, and Arf-bp1 - negatively regulate p53 protein, 
keeping levels low when p53 activity is not required (36). Mdm2 acts as a p53 inhibitor by binding 
to and sterically blocking p53 transactivation domains (37) and by serving as an E3 ubiquitin ligase 
to target p53 for proteasomal degradation (38,39,40). Mdm2 is a direct transcriptional target of 
p53, resulting in a negative-feedback loop where p53 can induce the expression of its own 
negative regulator (41,42). In response to stress signals, p53 is released from Mdm2 inhibitory 
effect, through any of several mechanisms: 1) stress-induced PTMs on both Mdm2 and p53, which 
disrupt the Mdm2-p53 interaction (43); 2) oncogene-induced sequestration of Mdm2 by p14ARF 
(p19Arf in mouse), a nucleolar protein encoded by the INK4a/Arf locus (44); and 3) nucleolar 
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stress-triggered ribosomal protein-Mdm2 interaction, that prevents Mdm2-mediated p53 
ubiquitination (45). Like Mdm2, the related protein Mdm4 (also known as MdmX) binds the 
amino-terminal region of p53. Mdm4 does not possess E3 ubiquitin ligase activity, therefore it 
contributes to p53 degradation by dimerizing with Mdm2 and increasing its activity (36). 
The importance of Mdm2 and Mdm4 in restricting p53 activity was shown through the generation 
of knock-out mice, which display early embryonic lethality. This phenotype results from 
uncontrolled p53 activity, as demonstrated by the complete rescue of lethality by concomitant 
knock-out of Trp53 (46,47,48). Recently, the Zhang lab showed that it is the ability of Mdm2 to 
heterodimerize with Mdm4, which is important to suppress p53 activity, and not its E3 ligase 
function (49). Consistent with their central role in negatively regulating p53, Mdm2 and Mdm4 
are frequently amplified in several tumor types (43).  
2.1.6 Cytoplasmic functions of p53 
In addition to its nuclear function as a transcription factor, p53 was shown to have additional 
activities (Fig. 5). The first p53 cytoplasmic function to be characterized was the induction of 
apoptosis in the presence of transcription inhibitors, which led to the discovery that p53 can 
trigger apoptosis by promoting mitochondrial outer membrane permealization (MOMP) (50,51). 
MOMP is controlled by the Bcl-2 family of apoptosis regulators, characterized by the presence of 
Bcl-2 homology (BH) domains. This family comprises three categories of proteins: 1) the pro-
apoptotic effectors Bak and Bax that can oligomerize to create pores in the mitochondrial outer 
membrane and release pro-apoptotic factors from the intramembranous space; 2) the BH3-only 
proteins that stimulate Bax- or Bak-mediated pore formation, including Bim, Bid, Bad, Puma and 
Noxa; and 3) the anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1, which bind Bak and Bax to 
prevent their oligomerization. p53 was proposed to regulate MOMP through two main 
mechanisms: mitochondrial apoptosis and cytoplasmic apoptosis. The first model suggests that, 
upon stress signals, p53 translocates to the mitochondria where, through binding and 
sequestration of the anti-apoptotic effectors Bcl-2, Bcl-xL and Mcl-1, it allows derepression of Bak, 
prompting pore formation and cytochrome c release. The second model posits that, under normal 
19 
 
conditions, p53 is kept inactive in the cytoplasm in a complex with Bcl-xL; in response to stress, 
nuclear p53 induces the expression of several target genes, including Bbc3/Puma, which is then 
able to bind Bcl-xL and liberate p53. Free p53 activates Bax in a "hit-and-run" fashion (i.e. through 
transient protein-protein interactions), promoting its mitochondrial translocation and homo-
oligomerization, thus inducing the MOMP and cytochrome c release. Cytochrome c binds Apaf1 
(apoptotic protease-activating factor 1), inducing the assembly of seven Apaf1 monomers into an 
oligomeric complex termed the apoptosome that activates the initiator caspase, procaspase 9. 
Caspase 9 cleaves and activates the effector caspases, caspase 3 and caspase 7, which then 
initiate apoptosis. Both models highlight an interconnection between nuclear and cytoplasmic 
p53 activities, since the mitochondrial pathway components Bax, Puma, Noxa and Bid are also 
direct p53 target genes (52,53,54).  
p53 activities at mitochondria are not only restricted to the regulation of apoptosis: in response to 
oxidative stress, p53 can induce necrosis, an irreversible tissue destruction characterized by cell 
lysis and inflammation. p53 accumulates in the mitochondrial matrix and binds cyclophilin D 
(CypD), triggering mitochondrial permeability transition pore (PTP) opening (55). PTP opening 
leads to an increase in unselective permeability to solutes and dissipates the cellular membrane 
potentials, leading to organelle swelling, rupture, and subsequent cell death (56). 
Cytoplasmic p53 was also shown to play a role in the regulation of macroautophagy (hereafter 
referred to as autophagy), a catabolic process that allows the sequestration and subsequent 
lysosomal degradation of macromolecules for reuse. Autophagy can serve either as a pro-survival 
strategy under metabolic stressful conditions, or as a means to remove damaged and potentially 
harmful structures, hence functioning as a tumor suppressive mechanism. When taken to 
extremes, autophagy can lead to cell death. Conversely, autophagy can constitute an important 
way for tumor cells to survive to a challenging microenvironment. Given that autophagy can have 
both tumor suppressive and tumor promoting activities, p53 can both positively and negatively 
regulate it in a context-dependent manner by acting at multiple levels on the Ampk-mTor axis, an 
important pathway involved in modulating metabolism and growth control (57). 
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Fig. 5 - p53-induced cell death: the cytoplasmic, the mitochondrial and the necrotic program. 
Source: Comel A et al., FEBS Letters 2014, vol. 588(16): 2600-2609 (52) 
Cytoplasmic p53 is also involved in the regulation of cell metabolism: by binding to G6PD (glucose-
6-phosphate dehydrogenase), the first and rate-limiting enzyme of the pentose phosphate 
pathway (PPP), p53 suppresses glucose consumption and NADPH (nicotinamide adenine 
dinucleotide phosphate) production, preventing the glycolytic flux that is associated with 
malignant cell growth (58). Moreover, p53 plays a role in the regulation of oxidative stress by 
interacting with the primary antioxidant enzyme MnSOD (manganese superoxide dismutase) and 
inhibiting its activity (52,54,59,60). 
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2.2 Transcriptional regulation by p53 
2.2.1 The p53 response element 
p53 functions primarily as a tetrameric transcription factor that binds, in a sequence-specific 
manner, to p53 response elements (p53-RE) in DNA. The p53-RE is classically defined by the 
combination of two decameric half sites, each with the consensus 5'-RRRCWWGYYY-3' (R=purine, 
W=A or T, Y=pyrimidine), prevalently placed one next to the other or, with lower incidence, 
separated by a spacer of 1-13 bp (Fig. 6) (61,62). These p53 binding motifs were initially described 
to often reside in the 5′ promoter-enhancer region or in the first intron of genes (63); recently this 
picture has been revised by the generation of genome-wide p53 binding maps, which show that 
p53 also associates with distal locations in the genome and binds DNA in a sequence-independent 
manner, probably through the interaction with other DNA-binding proteins (62,64). 
 
Fig. 6 - The p53 response element. 
Position weight matrix (PWM) of the consensus p53-RE (JASPAR database (65)). The height of a letter at 
each given position is proportional to the frequency of a particular nucleotide at that position. 
The p53 binding ability and its transactivation function are influenced by the sequence of the two 
half-sites as well as their mutual orientation (66). Using cooperativity mutants that can form 
weaker or stronger interactions between the p53 monomers, the Stiewe group showed that the 
p53 target genes can be functionally separated into two main classes based on the sequence 
similarity of their p53 regulatory elements to the canonical motif. Low cooperativity sites (bound 
by interaction-impaired mutants) are enriched for cell cycle progression genes and consist in high 
affinity p53 binding sites characterized by the classical consensus motif and shorter spacer length; 
high cooperativity sites instead (bound by strongly interacting mutants) are enriched for apoptotic 
genes and show reduced similarity to the p53 consensus motif and longer spacer length. The DNA 
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binding cooperativity of p53 is thereby important to recognize degenerate response elements and 
increase the spectrum of p53 target genes (67). The importance of keeping transcriptional 
regulation by p53 under tight control is exemplified by the observation that single nucleotide 
polymorphisms (SNPs) in functional p53-REs are infrequent due to negative selection, leading to 
the concept that such polymorphisms would likely be detrimental and are therefore purified from 
the population (68).  
2.2.2 p53 target genes 
The experimental evidence of p53 protein binding on the p53-RE close to the transcription 
initiation site of a gene is one of the criteria used to identify p53 target genes, and is usually 
coupled with the demonstration that the gene is differentially expressed when wild-type p53 is 
activated, but not when wild-type p53 is silenced, mutant p53 is present or the p53-RE is 
mutated. Several p53 direct targets associated to various tumor suppressive processes have been 
identified so far. The exact cell program specified by p53 activation depends on the cell type, the 
surrounding environment and the nature of the insult (63). In response to sustained or severe 
stress signals, p53 drives apoptosis of the damaged cells by up-regulating components of both the 
extrinsic and intrinsic death pathways, such as Bax, Bid, Fas, Pmaip1/Noxa and Bbc3/Puma, 
amongst others. In some cases, p53 responds to stress by inducing a temporary or a permanent 
cell cycle arrest through Cdkn1a/p21 expression. Beside senescence and cell death, p53 has also 
been shown to prevent tumor development through the regulation of cellular metabolism. Unlike 
normal differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation to 
generate the energy needed for cellular processes, most cancer cells rely on glycolysis even under 
normal aerobic conditions, a phenomenon termed the Warburg effect. p53 has been described to 
counteract the Warburg effect by lowering the glycolytic rate and promoting mitochondrial 
respiration by regulating the expression of Tigar, Sco2 and Gls2 (57). Moreover, p53 can activate 
autophagy by inducing Ulk1, Dram, Sesn1 and 2, and a set of autophagy core machinery-encoding 
genes (59,69).  
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These are just few examples of a continuously growing list of p53 target genes, owing to the rapid 
progression of high throughput analyses. 
2.2.3 Genome-wide analysis of the p53 network 
With the advent of technologies that can reveal p53 occupancy and measure expression changes 
of a large number of transcripts, new p53 target genes continue to be uncovered. The first of 
these studies analyzed the expression profiles of cell lines with inducible Trp53 using microarrays 
and observed that the p53 response depends on the levels of p53 protein, on the cell type and on 
the inducing agent, and involves genes belonging to different functional categories and with 
different kinetics in activation and repression (70). The ability to characterize p53-DNA 
interactions in a high-throughput manner using chromatin immunoprecipitation (ChIP) followed 
by hybridization on oligonucleotide arrays (ChIP-on-chip), allowed to expand the knowledge on 
the p53 regulatory network and led to the first indication that some p53 binding sites lie outside 
the promoter-proximal region (71,72). As soon as it became possible to generate whole-genome 
maps of p53 binding sites, initially through ChIP followed by paired-end ditag PET sequencing 
(ChIP-PET), and later by deep sequencing (ChIP-Seq), the p53 binding motif was better 
characterized, the observation that p53 binding sites also existed at large distances from 
transcription start sites (TSSs) was reinforced, and novel p53-regulated pathways were 
discovered, such as the Wnt signaling pathway or autophagy (73,74). Distal binding of p53 was 
associated to the regulation of non-coding RNA (ncRNA) species, such as microRNAs (75) and long 
intergenic non-coding RNAs (lincRNAs) (76,77), or showed chromatin features characteristic of 
enhancers. p53 binding at enhancer regions was shown to have opposing functions: to be one of 
the mechanisms underlying p53-mediated gene repression in mouse embryonic stem cells (mESC) 
(78) and to have enhancer activity required for efficient transactivation of the interacting target 
genes in fibroblasts (79); these contrasting functions could represent cell type- or gene-specific 
p53 regulatory activities. Another important observation that came out from these genome-wide 
studies is that only a minor fraction of the genes bound by p53 in the promoter-proximal region is 
transcriptionally regulated (69). A deeper comprehension of how p53 determines the specificity of 
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its responses will come from the study of p53 PTMs and cofactors at specific genomic locations. 
For example, there are indications that p53 phosphorylation at Serine 46 plays a role in the 
transactivation of several genes, in particular the apoptotic ones (80). Several other mechanisms 
have been described for the regulation of specific genes, but a genome-wide characterization is 
still missing. Finally, the p53 response can be also regulated at the post-transcriptional level by 
microRNAs and RNA-binding proteins (RBPs), as shown in a recent translatome analysis in MCF7 
cells following Nutlin or doxorubicin treatment (81). 
Initially, the activity of p53 was mainly investigated in response to cellular stress stimuli in 
immortalized cancer cell lines. To investigate the p53-dependent response in normal cells to 
stress insults, several genome-wide analyses of p53 chromatin occupancy and gene expression 
profiling were performed (64,69,78,82), which led to the observation that p53 is bound to DNA 
already in unperturbed conditions or with low levels of constitutive stress, suggesting a role for 
p53 in the regulation of basal processes. The study of p53 under physiological conditions is 
presently a growing field of investigation. One of the first reports indicated a role for p53 in 
regulating kidney development (83). In spite of extensive research, our understanding of the 
detailed molecular mechanisms activated by p53 remains incomplete. Several questions are left 
unanswered: for instance, what confers target gene selectivity to the p53 response and how cell 
fate in response to stress is determined. 
2.2.4 Transcriptional repression by p53 
p53's role as a transcriptional activator is well-documented. Instead, the mechanisms underlying 
transcriptional repression by p53 are still a matter of debate and can be grouped in direct (DNA 
binding-dependent) and indirect (DNA binding-independent) mechanisms (35). p53 may either 
displace other transcriptional activators and components of the transcriptional machinery by 
occluding their binding site on DNA, or recruit co-repressors and chromatin-modifying factors, 
such as histone deacetylases, which then block gene expression (35). Moreover, p53 has been 
proposed to mediate repression by interfering with distal enhancer activity (78). p53 also 
suppresses transcription indirectly by regulating the expression of microRNAs: in this setting, p53 
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facilitates not only the transcription of microRNA precursors, but also their processing into 
mature, active forms (75). Furthermore, p53 has been proposed to execute widespread gene 
repression, by activating a specific lincRNA, lincRNA-p21, which is believed to interact with 
hnRNP-K (heterogeneous nuclear ribonucleoprotein K) to silence target genes (76). Recently this 
model of lincRNAs regulating the expression of multiple genes in trans has been challenged by the 
generation of lincRNA-p21 conditional knock-out mice and the discovery that, in response to DNA 
damage, lincRNA-p21 acts in concert with hnRNP-K to induce p53-mediated activation of its 
neighboring gene Cdkn1a/p21, indicating a cis regulatory model (84). p21 mediates p53-
dependent transcriptional repression by inhibiting Cdk-dependent phosphorylation of the Rb 
protein to keep E2f-regulated genes in an inactive state (35,85). 
Recently, the model of p53 mediating repression through direct association with target promoters 
was questioned. Several groups reported a lack of p53 binding sites in the vicinity of most 
repressed genes; moreover, the Huang laboratory noted a correlation between p53 binding 
strength and fold induction only for the activated genes but not for the down-regulated ones 
(62,67,69,78), and the Espinosa group observed that very few target genes showed a diminished 
transcription in a Global Run-On sequencing (GRO-seq) analysis following p53 activation by Nutlin 
treatment (86). Altogether these findings indicate that p53-mediated repression may be largely 
indirect. 
2.3 Dissecting p53 functions through mouse models. 
2.3.1 The Trp53 knock-out mouse 
Trp53 knock-out mice were generated by three different groups, in each case through disruption 
of the p53 DNA binding domain (21,22,23) and provided unequivocal evidence of the fundamental 
role played by p53 in tumor suppression. Loss of p53 led to a dramatic, and completely penetrant 
predisposition to spontaneous cancer development: most Trp53 null animals succumbing to 
tumors by 10 months of age. Trp53 heterozygous mice showed increased tumor susceptibility 
compared to wild-type mice, although with delayed incidence compared to Trp53 null animals. 
Trp53-/- mice most commonly died of T-cell lymphomas and a range of sarcomas, while Trp53+/- 
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mice predominantly developed mesenchymal cancers (with a preponderance of osteosarcomas 
and soft-tissue sarcomas). The reasons for these difference in tumor spectrum are still undefined. 
It is clear instead that the types of tumors developed reflect an inherent predisposition of the 
different genetic backgrounds examined (87). In addition to providing insights to p53 tumor 
suppressive function, Trp53 knock-out mice have also been used to prove the involvement of p53 
in the regulation of several physiological processes. The first observation regarded an initially 
underestimated role of p53 during embryonal development: a fraction of Trp53 null embryos, 
prevalently female embryos, displays defects in neural tube closure resulting in an overgrowth of 
neural tissue in the region of the mid–brain, a condition known as exencephaly (88,89). Moreover, 
p53 was shown to play a role in fertility by promoting embryo implantation through the induction 
of Lif (leukaemia inhibitory factor) expression (90,91). 
2.3.2 p53 functions in tumor suppression: apoptosis and cell cycle arrest 
Apoptosis and cell cycle arrest were the first p53 functions to be described: it was back in 1992 
when p53 was named the 'guardian of the genome' for its role in maintaining genome stability 
and integrity in response to DNA damage (92). In this model, p53 induces a transient G1 arrest in 
response to DNA damage signals, allowing cells to repair their genome before proceeding into cell 
cycle, and thereby limiting the propagation of potentially oncogenic mutations. One year later, 
two groups reported that Trp53 null thymocytes are deficient in radiation-induced apoptosis, 
demonstrating the importance of p53 in the genotoxic and apoptotic responses and providing the 
first insights into p53 tumor suppressive mechanisms (93,94). 
The general importance of p53 in preventing cancer was further demonstrated by crossing various 
tumor-prone mouse strains onto a p53-deficient background. In most of these studies, p53 loss 
correlates with acceleration of tumorigenesis, showing that p53 acts like a brake downstream of 
several oncogenic pathways. One of the first studies along this line analyzed a transgenic model of 
choroid plexus papillomas initiated by the inhibition of the Rb protein activity by a fragment of 
Large T-Antigen (T121), leading to inappropriate cell proliferation. This hyper-proliferation activates 
p53 to induce apoptosis, resulting in slow-growing tumors. When the T121 transgenic mice are 
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crossed onto a Trp53 null background, tumorigenesis accelerates dramatically, indicating that 
p53-dependent apoptosis is important to prevent tumor development (95).  
Apoptosis is not the only means through which p53 can suppress tumorigenesis. The Lozano 
group studied the survival of knock-in mice expressing p53R172P, a mutant p53 protein that is 
unable to induce apoptosis but can induce a partial cell cycle arrest in response to DNA damage, 
and corresponds to the p53R175P mutation that occurs in human tumors (96). Trp53R172P 
homozygous mice develop spontaneous tumors with a median of 11.5 months, while Trp53 null 
mice die with a median of 5.5 months, indicating that the residual ability of p53R172P to initiate a 
cell cycle arrest plays an important role in tumor suppression. Moreover, the lymphomas and 
sarcomas that eventually develop in these Trp53R172P/R172P mutant mice remain diploid, in contrast 
to the aneuploid tumors that develop in Trp53-/- mice, suggesting that preserved cell cycle 
checkpoint functions can inhibit genome instability (96). The inability of p53R172P to suppress the 
development of late-onset tumors, however, also supported a role for p53-mediated apoptosis in 
tumor suppression. Similar conclusions were drawn by the Stiewe group with another mouse 
strain expressing the cooperativity mutant p53E177R (97). Substitution of the negatively charged 
glutamic acid with a positively charged arginine produces a mutant with impaired ability to bind 
DNA, particularly at apoptotic genes. Trp53E177R/E177R mutant mice show impaired apoptotic 
response following radiation, but retain some activity in inducing cell cycle arrest and senescence, 
and in the regulation of metabolism and antioxidant defense. As above for the Trp53R172P/R172P 
mutant mice, Trp53E177R/E177R animals are more cancer prone than Trp53 wild-type mice, but retain 
some residual tumor suppressive activity when compared to Trp53 null animals (97). 
To dissect the contribution of the different p53 effectors to p53-mediated tumor suppression, 
several knock-out mice that lack particular p53 target genes were generated, including Cdkn1a- 
(98,99,100), Gadd45a- (101), Bbc3- (102,103), and Pmaip1-deficient mice (103). None of these 
mice can reproduce the dramatic cancer predisposition observed in Trp53 null mice. These genes 
are negligible for the maintenance of genome stability and inhibition of spontaneous tumor 
formation; however, some of them are clearly important for p53-mediated tumor suppression in 
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the presence of certain oncogenic driver mutation, as their inactivation results in acceleration of 
carcinogenesis in tumor-prone mouse models (104,105,106,107,108). 
2.3.3 p53 functions in tumor suppression: beyond apoptosis and cell cycle arrest 
In an attempt to unveil the contribution of p53 transcriptional activity to tumor suppression, the 
Attardi team generated transactivation domain Trp53 mutant knock-in mice, with alterations in 
the first (p5325,26), second (p5353,54), or both TADs (p5325,26,53,54) (109). The p5353,54 mutant retains 
intact transactivation function, as indicated by a global gene expression profile of HrasV12; 
Trp5353,54 MEFs that is indistinguishable from that of wild-type cells, and by the ability to suppress 
KrasG12D-driven lung tumors. The p5325,26 mutant instead is severely compromised for 
transactivation of most p53 target genes, including Cdkn1a, Bbc3 and Pmaip1, and cannot trigger 
cell cycle arrest and apoptosis in response to acute DNA damage, but can induce senescence in 
HrasV12 MEFs. Despite its partial impairment in transcriptional activation, p5325,26 retains the 
capacity to suppress the growth of tumors that are initiated by different oncogenic lesions and in 
a range of tissue types (110). In contrast, the transactivation-dead p5325,26,53,54 mutant completely 
lacks tumor suppressive potential, demonstrating that p53 transactivation is essential for tumor 
suppression, although this requirement reflects the limited transcriptional activity of p5325,26 
mutant (109,110). Gu and coworkers confirmed the observation that tumor suppression can be 
achieved even in the absence of full transcriptional activation of Cdkn1a, Bbc3 and Pmaip1 by 
generating knock-in mice expressing p533KR, in which three lysines known to be acetylated in vivo 
are mutated to arginines (K117R, K161R, K162R) (111). In response to DNA damage, MEFs from 
Trp533KR/3KR mice fail to undergo apoptosis, cell cycle arrest and senescence but retain the ability 
to activate the metabolic genes Gls2, Tigar and Gpx1. Trp533KR/3KR mice don't show the 100% 
penetrant predisposition to spontaneous tumors of Trp53-/- animals, suggesting that the ability to 
regulate energy metabolism and reduce the levels of reactive oxygen species (ROS) are crucial for 
tumor suppression. Moreover, these data indicate the importance of acetylation in modulating 
the p53 response (111). However, these studies described an impaired transcription of the 
classical p53 effector genes Cdkn1a, Bbc3 and Pmaip1, but couldn't formally prove a complete 
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suppression, leaving the question open whether these genes could still prevent tumor 
development when expressed at low levels. This issue was addressed by the Strasser group 
through the generation of Cdkn1a-/- Bbc3-/- Pmaip1-/- mice (112). Strikingly, none of the triple 
knock-out animals develops spontaneous tumors up to 500 days, whereas all Trp53-/- mice 
succumb to lymphomas and sarcomas by 250 days. The authors noted that DNA repair upon acute 
DNA damage is delayed in p53-deficient cells relative to wild-type or triple knock-out cells, 
suggesting that p53's role in maintaining genome integrity may have protected these animals 
from spontaneous tumor development (112). Overall, these studies demonstrate that suppression 
of spontaneous tumorigenesis can still be achieved when the ability to induce apoptosis and cell 
cycle arrest is impaired. 
2.3.4 Oncogene-driven tumor suppressive pathways: a focus on Myc 
c-Myc (henceforth Myc) was initially identified as the human homologue of a retroviral oncogene 
of the MC29 avian tumor virus that caused myelocytomatosis in chickens (113). Several years 
after its discovery, it became clear that Myc is a transcription factor implicated in the control of 
normal cell proliferation (114). Aberrant Myc regulation is often observed in cancer and is the 
result of virus-mediated insertional mutagenesis, gene amplification or chromosomal 
translocation. In addition, Myc is deregulated by, and is an effector of, many additional 
mechanisms, including a variety of oncogenic signaling pathways (e.g. Wnt, Notch, Ras, ...) and 
activation of hormones or growth factors receptors (114). Pathological activation of Myc has two 
opposite and paradoxical effects: on one side Myc overexpression induces cellular transformation 
and hyper-proliferation, while on the other side it activates intrinsic tumor surveillance pathways 
aimed at restraining the expansion of pre-cancerous cells. The best characterized Myc-induced 
tumor suppressive arm is the p19Arf/Mdm2/p53 pathway. Oncogenic Myc activates p19Arf, that, as 
mentioned before, is able to stabilize p53 by binding and antagonizing Mdm2 (115,116). Arf 
accumulation and consequent p53 activation was described to be the result of Myc-induced 
disruption of the interaction between Arf and its E3 ubiquitin ligase Ulf (117).  
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The first p53-dependent response to be characterized was apoptosis: it was noticed that ectopic 
expression of Myc sensitizes cells deprived of extracellular survival factors to programmed cell 
death (118,119). Abrogation of Myc-induced cell death is crucial for cellular transformation, 
setting the selective pressure to inactivate Arf or p53 (116). An in vivo model to test the relevance 
of this pathway during lymphomagenesis is the Eµ-myc transgenic mouse model (120), in which 
Myc is under control of the immunoglobulin heavy chain enhancer, a genetic alteration 
resembling the chromosomal translocation observed in human Burkitt's lymphomas 
(121,122,123,124,125). Myc overexpression in B-cell progenitors leads to increased proliferation 
and reduced differentiation from pre-B to mature B cells (120). In the pre-tumoral stage, the high 
rates of cell divisions driven by Myc are counter-balanced by p53-induced apoptosis. This 
constitutes the main barrier against Myc's oncogenic potential and sets the selective pressure to 
inactivate the p53 pathway in Myc-induced lymphomas (126,127). Disruption of apoptosis by Bcl2 
overexpression is sufficient to accelerate Myc-induced tumorigenesis and alleviate the pressure to 
inactivate p53, indicating that p53 tumor suppressive function, in this particular tumor type, relies 
mainly on programmed cell death (128,129). When apoptosis is disrupted, p53 retains some 
residual tumor suppressor activity associated to senescence (97,130,131). However, since Myc 
also regulates proliferation in normal cells, p53 activation should be restrained to situations 
wherein Myc signaling is oncogenic. Evan and coworkers showed that distinct threshold levels of 
Myc determine its output in vivo: low levels of Myc are required to drive proliferation, whereas 
elevated Myc levels are competent to engage the p19Arf/p53 tumor suppressor pathway and 
induce apoptosis (132).  
Of note, Arf loss does not always recapitulate p53 loss. For example, unlike Trp53-/- lymphomas, 
Ink4a/Arf-/- lymphomas are genetically stable and sensitive to chemotherapy (127), indicating that 
the p19Arf/Mdm2/p53 pathway is not the only intrinsic tumor suppressive program available in 
the cells. Analysis of early human pre-cancerous and cancerous lesions reveals molecular marks of 
DNA damage, leading to a model whereby oncogene-induced hyper-proliferation results in 
replication stress, DNA double-strand breaks formation and ROS-associated oxidative damage 
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(133). Activated oncogenes can induce a DNA damage response (DDR) that signals to p53 via a 
phosphorylation cascade that involves the Atm and Chk2 kinases and ultimately imposes a barrier 
to tumor development (134,135). The p19Arf and the DNA damage pathway can synergize to 
activate p53 and this can be exploited to promote more efficiently death of tumor cells (136). 
However, the p19Arf and the DDR are not the only Myc-induced pathways upstream of p53: for 
example, ribosomal stress has been shown to induce ribosomal proteins-mediated inhibition of 
Mdm2 E3 ligase activity, resulting in p53 activation (137). Moreover, Myc can also directly induce 
apoptosis in the absence of p19Arf by regulating Bim expression (138). 
2.3.5 Therapeutic promise of p53 reinstatement in tumors 
Induction of p53 in pre-cancerous cells elicits several tumor suppressive mechanisms that result in 
the elimination of the damaged cells and, as a consequence, are selected against during tumor 
development. Therefore, restoration of p53 function in tumors constitutes a very attractive 
strategy for cancer therapy. Using transgenic mice with conditionally activatable wild-type Trp53 
alleles, three groups showed that p53 restoration induces tumor regression, based on different 
p53 reinstatement approaches and tumor models (136,139,140). The Evan group used the 
p53ERTAM model (141) crossed with the Eµ-myc lymphoma model (120,136). In the p53ERTAM 
model, the modified hormone-binding domain of the estrogen receptor is placed in-frame at the 
3'-end of the coding sequence of the endogenous Trp53 gene, to create the p53ERTAM allele that is 
activated by the oestrogen synthetic analogue 4-hydroxytamoxifen (4-OHT). Administration of 4-
OHT allows a fast transition from a p53 null state to a functional p53 state (136). The Jacks 
laboratory inserted a transcription-translation stop casette flanked by loxP sites (LSL) in the first 
intron of the endogenous Trp53 locus. p53 expression was regulated through a ubiquitously 
expressed tamoxifen-inducible Cre recombinase to regress radiation-induced spontaneously 
arising lymphomas and sarcomas (139). Finally, the Lowe lab used a doxycycline-repressible p53 
short-hairpin RNA (shRNA) to conditionally regulate p53 expression in a mouse model of Ras-
induced liver carcinoma (140). Interestingly, although each model show tumor regression upon 
restoration of p53 function, the mechanisms of p53-mediated tumor suppression depend on the 
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tumor type: lymphomas undergo apoptosis, while sarcomas and liver tumors show features of 
cellular senescence. In the liver carcinoma model, p53-induced senescent cells produce 
inflammatory cytokines and an innate immune response, that contributes to tumor cell clearance, 
providing evidence of a non-cell autonomous tumor suppressive function of p53. These results 
imply that p53 reinstatement has therapeutic potential for cancer treatment. However, the Evan 
group reported tumor relapse after p53 induction due to the selection of resistant clones that 
have inactivated the p19Arf/p53 pathway (136), therefore therapies should be carefully planned. 
The main strategies for re-establishing p53 activity in tumors that are currently in clinical trials are 
the re-introduction of p53 in cancer cells through the use of gene therapy with replication-
deficient adenoviral vectors (142) and, for tumors that retain wild-type p53, small molecule drugs 
that mostly function by interfering with the p53 inhibitory ability of Mdm2 (143). To treat tumors 
with some mutant p53 proteins, scientists have developed small molecules that can refold p53 to 
a transcriptionally competent conformation (144). The development of such drugs raised some 
concerns about the potential toxicity that a systemic activation of p53 may cause in normal 
tissues: one can anticipate, however, that these molecules are likely to function much better in 
tumor cells, where upstream p53-activating signals are present and acute, compared to normal 
cells. 
2.4 Aim of the work 
The genetic programs used by the p53 tumor suppressor to direct stress-specific biological 
responses remain to be clarified. For example, it is still unclear whether p53 directly or indirectly 
represses the expression of target genes, or which are the cofactors or the effectors that 
cooperate with p53 to regulate gene transcription, or whether different target genes are 
activated in response to different stress stimuli or depending on the cellular context. To gain new 
insights into p53 biology, we used high-throughput sequencing to generate whole genome maps 
of p53 binding and gene expression profiles during tumor suppression and regression using a 
model of Myc-induced tumorigenesis and in response to a classical p53 activating stimulus, such 
as DNA damage. Through the comparison of these global p53 transcriptional programs we aim at 
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better understanding the regulatory mechanisms within the p53 network. Moreover, the 
components of p53 transcriptional programs may be critical tumor suppressor genes, paving the 
way for functional studies and hopefully the identification of candidate targets for future 
therapeutic applications. 
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3 Materials and Methods 
3.1 Mouse breeding and genotyping 
The following mouse strains were used for this study: Eµ-myc transgenic mice (120), p53ERTAM 
mice (141), LSL-p53 mice (139), p53 KO (p53Δ) mice (21), Arf+/- mice (145) and C57/Bl6 wild-type 
mice (Harlan). All animals were maintained on a C57/Bl6 background (except p53ERTAM mice that 
were on a mixed background) and bred to obtain the various genotype combinations described in 
this thesis.  
Primers used for genotyping were listed below.  
Strain Primers 
Eµ-myc 
GGTTTAATGAATTTGAAGTTGCCA 
TTCTTGCCCTGCGTATATCAGTC 
p53ERTAM 
CCTCCAGCCTAGAGCCTTCCAAGC 
GGTGAGATTTCATTGTAGGTGCC 
GCACACAAACTCTTCACCCTGC 
LSL-p53 
CTTGGAGACATAGCCACACTG 
AGCTAGCCACCATGGCTTGAGTAAGT 
CAACTGTTCTACCTCAAGAGCC 
p53 KO 
AGCGTGGTGGTACCTTATGAG 
GGATGGTGGTATACTCAGAGC 
GCTATCAGGACATAGCGTTGG 
 
Experiments involving animals were performed in accordance with the Italian laws (D.L.vo 116/92 
and following additions), which enforce EU 86/609 directive (Council Directive 86/609/EEC of 24 
November 1986 on the approximation of laws, regulations and administrative provisions of the 
Member States regarding the protection of animals used for experimental and other scientific 
purposes). 
3.2 Primary mouse B and non-B cells and lymphomas  
B cells were extracted as described. Briefly, for control (C) and pre-tumoral (P) samples, spleens of 
6–7 weeks old Eµ-myc transgenic mice with no infiltration of peripheral lymph nodes were used. 
Spleens from C57/Bl6 wild-type mice were collected four hours after exposure to 7 Gy whole-
body irradiation and from a control cohort of mice. Single-cell suspensions were obtained by 
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pressing the spleens through nylon cell strainers and subsequent hypotonic lysis of red blood 
cells. To isolate B cells, we incubated single-cell suspensions with B220 MicroBeads (Miltenyi 
Biotech) and enriched them by magnetic cell sorting (MACS), according to the manufacturer 
instructions (Miltenyi Biotech). The column flow through was kept to represent the non-B cell 
population.  
Lymphoma samples (or tumors, T) composed primarily of tumor cells, were dissected from 
infiltrated lymph nodes and not purified further. At this stage, samples were directly processed 
for the different assays.  
Lymphoma cells were grown in 1:1 ratio of irradiated NIH-3T3 conditioned medium and fresh 
medium (DMEM and IMDM (1:1), 10% fetal bovine serum, 2mM L-Gln, 1% 
penicillin/streptomycin, 1% non-essential amino acids and 0,2% β-mercaptoethanol) and 
maintained at 37°C with 5% CO2.  
Retroviral-mediated gene transfer was performed using Phoenix packaging cells. Eµ-myc LSL-p53 
lymphoma cells were infected with pMI CreERT2-ires-Puro (146) and Eμ-myc Arf-/- Trp53+/+ 
lymphomas cells with pLEPG shp53.1224 (147). 
3.3 Lymphoma Transplantation and In Vivo Treatment  
For transplants, lymphoma cells were thawed immediately before use, washed, counted, and 
injected intravenously (0.5 x 106 cells/mouse in 300 μl phosphate-buffered saline [PBS]) into 
multiple genetically matched wild-type mice (for Eμ-myc p53ERTAM lymphomas, recipient mice 
were immunosuppressed with 4 Gy 3–6 hr prior to transplantation). For short-term p53 
restoration studies, tamoxifen (1 mg/300 μl of peanut oil/mouse) or carrier was administered 
once by intraperitoneal injection, when tumors were palpable.  
3.4 Chemicals  
Doxorubicin hydrochloride was purchased from Sigma-Aldrich Srl, dissolved in water and used 1 
mM (0.6 mg/ml). (+)-and (-)-Nutlin were purchased from Cayman Chemical, dissolved in DMSO 
and used at 10 mM. 4-Hydroxytamoxifen was purchased from Sigma-Aldrich Srl, dissolved in 
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ethanol and used 0.1 mM. Tamoxifen was dissolved in peanut oil (Sigma-Aldrich Srl) and used 3 
mg/ml.  
3.5 Western blotting 
5-10 x 106 cells were lysed with RIPA Buffer (20 mM HEPES at pH 7.5, 300 mM NaCl, 5 mM EDTA, 
10% Glycerol, 1% Triton X-100, supplemented with protease inhibitors (Mini, Roche) and 
phosphatase inhibitors 0.4 mM Ortovanadate, 10 mM NaF) and sonicated. Cleared lysates were 
electrophoresed and immunoblotted with the indicated primary antibodies: p53 (NCL-p53-CM5p) 
from Novocastra laboratories and Vinculin (V9264) from Sigma. After incubation of the 
membranes with appropriate secondary antibodies, infrared imaging was performed with LiCor 
Odyssey System. 
3.6 Flow citometry: cell cycle and apoptosis analysis 
To analyze cell cycle and apoptosis, 1 x 106 live cells were resuspended in 1 ml of PBS and fixed by 
adding 2 ml of ice-cold absolute ethanol and kept at 4°C for at least 30 minutes. Cells were 
washed once with 1 ml of PBS 1% BSA and stained overnight with 1 ml 50 µg/ml propidium iodide 
(PI) and 250 µg/ml RNaseA at 4°C. 50000 total events were analyzed by FACS. All the FACS data 
were acquired using a FACSCalibur machine (Becton Dickinson) and then analyzed by using FlowJo 
software (TreeStar). 
3.7 Chromatin Immunoprecipitation  
Cells were processed as described above.  
To minimize inter-individual variation we decided to process ChIP samples of Eμ-myc control and 
pre-tumoral mice, and C57/Bl6 wild-type mice (Harlan) in pools of ten age- and sex-matched 
animals, while, due to the clonal nature of lymphomas, we kept tumor samples separated and 
analyzed four Eμ-myc p53ERTAM lymphomas, three Eμ-myc Arf-/- Trp53+/+ and three Eμ-myc LSL-
p53 lymphomas. For ChIP-Seq analysis of p53, lysates from 50 x 106 B cells were 
immunoprecipitated with 10 μg p53 antibody (NCL-p53-CM5p - Novocastra laboratories). p53 
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antibody specificity was tested by ChIP-Seq analysis in total splenic cells from Trp53-/- mice four 
hours after 7 Gy of X-ray radiation.  
Cells were fixed by addition of 1% formaldehyde for 10 min. Fixation was stopped by addition of 
0,125 M glycine. Cells were washed three times in PBS, resuspended in SDS buffer (50 mM Tris at 
pH 8,1, 0,5% SDS, 100 mM NaCl, 5 mM EDTA, and protease inhibitors) and stored at -80 °C before 
further processing for ChIP. Cells were pelleted by centrifugation, and suspended in 4 ml of IP 
Buffer (100 mM Tris at pH 8.6, 0.3% SDS, 1.7% Triton X-100, and 5 mM EDTA). Cells were 
disrupted by sonication with a Branson 250 sonicator, performing 5 cycles of 30 sec 30% 
amplitude, yielding genomic DNA fragments with a bulk size of 100–400 bp. 1 ml of diluted lysate 
was precleared by addition of 25 μl of blocked protein A beads (50% slurry protein A-Sepharose, 
Amersham; 0.5 mg/ml fatty acid-free BSA, Sigma; and 0.2 mg/ml tRNA,Sigma, in TE). Samples 
were immunoprecipitated overnight at 4°C with polyclonal antibodies. Immune complexes were 
recovered by adding 50 μl of blocked protein A beads and incubated for 4 hr at 4°C. Beads were 
washed with successive washes in 1 ml of Mixed Micelle Buffer (20 mM Tris at pH 8.1, 
150mMNaCl, 5mMEDTA, 5% w/v sucrose, 1% Triton X-100, and 0.2% SDS), Buffer 500 (50 mM 
HEPES at pH 7.5, 0.1% w/v deoxycholic acid, 1% Triton X-100, 500 mM NaCl, and 1 mM EDTA), LiCl 
Detergent Wash Buffer (10 mM Tris at pH 8.0, 0.5% deoxycholic acid, 0.5% NP-40, 250 mM LiCl, 
and 1 mM EDTA), and TE (pH 7.5). DNA was eluted in TE 2% SDS and crosslink reversed by 
incubation overnight at 65 °C. DNA was then purified by Qiaquick columns (Qiagen) and 
quantified using PicoGreen (Invitrogen). 2-10 ng ChIP DNA was prepared for HiSeq2000 
sequencing with TruSeq ChIP Sample Prep Kit (Illumina) following manufacturer instructions. For 
ChIP-qPCR analysis, DNA was amplified in Real-time PCR reactions with FAST SYBR Green Master 
Mix (Applied Biosystems). 
3.8 RNA extraction and analysis 
Total RNA was purified onto RNeasy columns (Qiagen) and treated on-column with DNase 
(Qiagen). Complementary DNA (cDNA) was produced using the reverse transcriptase ImPromII 
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(Promega). 10 ng of cDNA were used for Real-time PCR reactions with FAST SYBR Green Master 
Mix (Applied Biosystems).  
For RNA-Seq, total RNA from 107 cells was purified using Trizol (Invitrogen), treated with Turbo 
DNase (Ambion) and purified with RNA Clean XP (Agencourt). 5 μg of purified RNA were then 
treated with Ribozero rRNA removal kit (Epicentre) and ethanol precipitated. RNA quality and 
removal of rRNA were checked with the Agilent 2100 Bioanalyzer (Agilent Technologies). Libraries 
for RNA-Seq were then prepared with the TruSeq RNA Sample Prep Kits v2 (Illumina) following 
manufacturer instruction (except for skipping the first step of mRNA purification with poly-T oligo-
attached magnetic beads).  
3.9 NGS data filtering and quality assessment  
ChIP-seq and RNA-seq NGS reads sequenced with the Illumina HiSeq2000 were filtered using the 
fastq_quality_trimmer and fastq_masker tools of the FASTXToolkit suite 
(http://hannonlab.cshl.edu/fastx_toolkit/). Their quality was evaluated and confirmed using the 
FastQC application (www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
3.10 Analysis of ChIP-seq data  
ChIP-seq NGS reads were aligned to the mm9 genome through the BWA aligner (148) using 
default settings. Peaks were called using the MACS software (v1.4)38 (149). Only peaks with p-
value < 1e-8 were retained. Peak enrichment was determined as log2(ChIPw - inputw), where ChIPw 
and inputw is the normalized count of reads in the peak region in the ChIP and in the 
corresponding input sample.  
3.11 Genome annotation  
Refseq mm9 gene model was used in the present study. The corresponding gtf and bed files were 
downloaded from the UCSC Table Browser.  
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3.12 RNA-seq data analysis  
RNA-Seq NGS reads were aligned to the mm9 mouse reference genome using the TopHat aligner 
(version 2.0.6). In case of duplicated reads, only one read was kept. Read counts were associated 
to each exon using the HTSeq software  
(http://www.huber.embl.de/users/anders/HTSeq/doc/overview.html). 
3.13 Identification of differentially expressed genes  
Differentially expressed genes (DEGs) were identified using the Bioconductor package DESeq2 
(30). In order to call DEGs over-genes when multiple isoforms are present, the rounded mean of 
counts over the isoforms is used. DEGs are defined as genes whose q-value relative to the control 
is lower than 0.05. Quantification of relative levels of total mRNA was calculated on B and non-B 
cells RNA-Seq data from 4 Trp53+/+ and 2 Trp53-/- mice in each condition, 4 Eμ-myc p53ERTAM 
lymphomas treated with 4-OHT and 3 Eμ-myc Arf-/- Trp53+/+ lymphomas following (-)-Nutlin and 
doxorubicin treatment relative to controls. All RNA-Seq experiments in Eμ-myc lymphoma 
samples were performed on biological and technical replicates. 
3.14 Other bioinformatic and statistical analyses  
Statistical analysis, heatmaps, hierarchical clustering of RNA-seq data and other visual 
representations of the data were performed using R and Bioconductor packages (150). Two-tailed 
Student’s t-test was used to calculate p-values. 
3.15 Motif search  
Sequences from the reference genome were extracted and subjected to a de novo motif search 
using MEME-ChIP (151). The discovered motifs were compared with known motifs from the 
JASPAR database using TOMTOM (152). The occurrence of the p53 motif at the genomic intervals 
analyzed was calculated by the FIMO (Find Individual Motif Occurences) algorithm (153) (p-
value<1 x 10-5). 
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3.16 Gene ontology biological process analysis 
Functional annotation analysis to determine enriched Gene Ontology Biological Processes was 
performed using DAVID (154,155), GREAT (156) or GO terms in the biological process ontology, as 
specified in the figure legends. 
3.17 Primer Design and List of Primers 
Primers for ChIP and mRNA analysis were designed by using primer design software (Primer-
BLAST).  
Gene  Primers for ChIP-PCR  
Cdkn1a 
TAGCTTTCTGGCCTTCAGGA 
GGGGTCTCTGTCTCCATTCA 
Bbc3 
CCGTTAGTCTGAGCGTACTCC 
CGCTTGACACACTGACACACT 
AchR 
AGTGCCCCCTGCTGTCAGT  
CCCTTTCCTGGTGCCAAGA  
Gene Primers for RT-PCR 
Cdkn1a 
CTGGGAGGGGACAAGAG 
GCTTGGAGTGATAGAAATCTG 
Bbc3 
GAGACAAGAAGAGCAGCATCG 
AAGAGATTGTACATGACCCTCCA 
Pmaip1 
CAGAGCTACCACCTGAGTTCG 
TACACTTTGTCTCCGATCTTCCT 
Trp53 
CGCTGCTCCGATGGTGAT 
TGGCGAAAAGTCTGCCTGTC 
Tbp 
TAATCCCAAGCGATTTGCTG 
CAGTTGTCCGTGGCTCTCTT 
3.18 Ingenuity pathway analysis (IPA)  
Upstream Regulator Analysis was performed using QIAGEN’s Ingenuity Pathway Analysis (IPA, 
QIAGEN Redwood City, www.qiagen.com/ingenuity). Statistical significance and p-values were 
determined by IPA using a Fisher's Exact Test.  
3.19 Vector and shRNA library construction 
A miR-30-based shRNA library was designed to target 330 p53 target genes, that were strong 
candidates for mediating tumor suppression. 97-base-pair gene-specific hairpins were selected 
from the Hemann lab shRNA database (http://euphrates.mit.edu/cgi-bin/shRNA/index.pl) to 
generate an shRNA library subdivided into 30 pools of 55 shRNAs each targeting 11 genes (5 
41 
 
shRNA/gene). 121-base-pair oligonucleotides (including the miR-30-shRNA precursor, the EcoRI 
site and a pool-specific barcode) were synthesized on a 12k customized oligonucleotide array 
(CustomArray). Pool-specific PCR products were individually cloned in MLS vector. Viruses were 
produced by transient transfection of Phoenix ecotropic packaging cell line.  
3.20 Haematopoietic stem and progenitor cell isolation and in vivo adoptive 
transfer 
Single-cell suspensions of Eµ-myc HSPCs were prepared by resuspending ED 12.5-14.5 fetal livers 
in stem cells medium (DMEM and IMDM (1:1), 10% stem cell serum (Stem Cell Technologies), 
2mM L-Gln, 1% penicillin/streptomycin, 0,2% β-mercaptoethanol, 0,4% WEHI-3B conditioned 
medium) supplemented with 2 ng/ml IL-3, 2 ng/ml IL-6 and 20 ng/ml SCF. Cells were retrovirally 
transduced with shRNA pools or individual shRNAs. After short-term in vitro expansion, 1-2 × 106 
HSPCs were transplanted by tail-vein injection into sublethally irradiated (7 Gy) 8- to 10- week-old 
syngenic C57/Bl6 females. Recipient mice were administered neomycin (1 mg/ml, Sigma-Aldrich) 
in the drinking water for 2 weeks after transplantation. 
3.21 Tumour sequencing 
DNA was extracted from lymphoma cell pellets with Puregene A Core Kit (Qiagen). shRNAs were 
amplified by PCR, from the genomic tumor DNA, with vector-specific primers (forward primer, 5′- 
AATGATACGGCGACCACCGACTAAAGTAGCCCCTTGAATTC -3′, barcoded reverse primer, 5′- 
CAAGCAGAAGACGGCATACGA-NNNNNN-TAGTGAAGCCACAGATGTA -3′). The primers also 
contained the P5 and P7 adaptor sequences required for sequencing on the Illumina HiSeq 2000 
platform. After amplification, PCR products from individual tumor samples amplified with specific 
barcodes were purified, quantified and pooled. Approximately 2 × 106 50-base-pair reads were 
acquired for each sample. By reading 50 nucleotides into the amplicon starting from the shRNA 
guide strand, we were able to deconvolute the different tumour samples according to the sample-
specific barcode. The specific sequences were subsequently identified by comparing the reads 
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with the original library sequences using the BWA algorithm, and the relative distribution was 
calculated.  
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4 Results 
4.1 Characterization of the p53-dependent response to acute DNA damage 
4.1.1 Genome-wide analysis of p53 binding following ionizing radiation 
DNA damage is one of the best characterized p53 activating stimuli. Trp53 null thymocytes are 
deficient in radiation-induced apoptosis, demonstrating the importance of p53 in the response to 
genotoxic stress (93,94). Given the pivotal role played by p53 in the response to genotoxic injury, 
we explored the transcriptional activity of p53 following ionizing radiation (IR)–induced DNA 
damage in vivo with a combination of ChIP-Seq and RNA-Seq experiments in wild-type and Trp53-
deficient mice: we thus compared p53 binding and mRNA expression profiles in different cell 
types, including mature splenic B cells, defined by the presence of the surface marker B220 
(henceforth "B cells"), and a myeloid-enriched population, constituted by the rest of the cells in 
the organ (B220-negative, "non-B cells"). Four hours after exposure to 7 Gy whole-body 
irradiation, cells were isolated and processed for the different assays immediately after 
purification without any in vitro culture. We first analyzed the genomic distribution of p53 in vivo 
in unperturbed and irradiated wild-type B and non-B cells, and in irradiated total splenic cells 
from Trp53-/- mice as a negative control for the specificity of the p53 antibody (Fig. 7). Stress 
stimulation greatly increased the total number of binding sites both in B and non-B cells (from 
around 2,000 sites in control to 20,000 in irradiated samples) (Fig. 7, Fig. 8). All p53 peaks 
identified in control samples were retrieved in the irradiated samples where they constituted 
some of the most enriched peaks (Fig. 7). Upon stress stimulation, p53 binding sites increased by 
ten-times and the overlap between p53 peaks in B and non-B cells went from 50% in controls up 
to 85% in irradiated samples. Moreover, all the binding sites in unperturbed samples were 
retrieved in either B and non-B cells upon irradiation.  
In all conditions, 30-40% of the p53 binding sites were located nearby an annotated transcription 
start site (-5 to +2kb from the TSS, henceforth referred to as "promoter"). The remaining peaks 
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were distal, and equally distributed among intra-and intergenic regions. With the increase in p53 
levels following acute DNA damage, the new binding sites distributed roughly proportionally on 
promoters, gene bodies and extragenic locations, resulting in a similar genomic distribution of p53 
peaks as in control samples (Fig. 8).  
We then performed motif analysis on the p53-bound sites and checked for the occurrence of the 
canonical p53 consensus motif (Jaspar database (65)): the p53-RE could be identified in 
approximately 10% and 30% of the promoter-proximal and distal p53 binding sites, respectively 
(Fig. 7, Fig. 9). At the remaining sites, p53 could be bound to weak variant sites or in a non-
sequence specific manner, through protein-protein interactions or chromatin looping. This notion 
was also supported by the observation that sites containing the p53 motif represented the high 
affinity sites as indicated by a clear correlation between the presence of the p53-RE and p53 
binding strength (Fig. 10). However, it should be noted that this was a preliminary analysis that 
didn't take into consideration weaker variant sites or p53 motifs with a spacer or half sites, 
therefore we could be underestimating the number of p53-REs identified. 
 
Fig. 7 - IR exposure increased both the binding intensity and the total number of p53 binding sites. 
Heatmaps showing library size-normalized ChIP-seq read counts for all p53-bound promoters (-5/+2 kb 
from the TSS), gene bodies (+2 kb from the TSS through 3'UTR) and intergenic regions (everything else) 
at chromosome 1 in B and non-B cells from control (mock) and irradiated (IR) Trp53
+/+
 mice and total 
splenic cells from irradiated Trp53
-/-
 mice, as indicated. Peaks are ranked from top to bottom by reads 
density in irradiated B cells. The occurrence of the p53 motif at the genomic intervals analyzed is 
calculated by the FIMO (Find Individual Motif Occurences) algorithm (153) (p-value<1 x 10
-5
) and 
indicated with blue lines on the left side of the heatmaps. 
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Fig. 8 - Genomic distribution of p53 binding sites. 
Percentages of p53 binding sites at promoters (-5/+2 kb from the TSS, red bar), gene bodies (+2 kb from 
the TSS through 3'UTR, green bar) and intergenic regions (everything else, blue bar) in B and non-B cells 
from control (mock) and irradiated (IR) wild-type mice. Absolute numbers of peaks are indicated above 
the bars and total numbers of peaks in the sample below the labels. 
 
Fig. 9 - Motif analysis and genomic distribution of p53-binding sites.  
Characterization of all p53-bound sites at promoters (-5/+2 kb from the TSS, red bar), gene bodies (+2 
kb from the TSS through 3'UTR, green bar) and intergenic regions (everything else, blue bar) in B cells 
and non-B cells from control (mock) and irradiated (IR) wild-type mice, for the occurrence of the p53 
motif as calculated by the FIMO algorithm (p-value<1 x 10
-5
). The percentage of p53-bound sites 
containing the p53-RE is indicated. 
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Fig. 10 - Stronger p53 binding sites are more likely to contain the consensus p53 motif. 
Peak enrichment of p53 binding sites that contain (grey boxes) or not (black boxes) the p53 motif in 
control (mock) and irradiated (IR) B and non-B cells. The boxes are drawn with widths proportional to 
the square-roots of the number of observations in the groups. 
To chart p53 binding sites at active promoters and enhancers, we characterized them for the co-
localization with the active promoter mark H3K4me3, the enhancer mark H3K4me1 and the 
activation mark H3K27ac, using our recently published ChIP-Seq dataset in mouse B cells (157). All 
p53-bound promoters were characterized by the presence of H3K4me3 and H3K4me1; moreover, 
the H3K27ac mark was identified at most promoter-proximal sites, indicating that p53 associated 
with regulatory elements that pre-existed in an active state in non-irradiated B cells (Fig. 11A). A 
major fraction of the p53-bound distal sites showed chromatin features characteristic of 
enhancers (high H3K4me1/H3K4me3 ratios) and were similarly partitioned on intra-and intergenic 
regions (Fig. 11B). The H3K27ac mark co-occurred at most of these sites, indicative of active 
enhancers. Distinct subsets of p53-bound promoters and enhancers, however, lacked H3K27ac: it 
would be interesting to study whether these elements would acquire the mark upon irradiation. 
There are few contrasting reports in the literature about the role played by p53 at enhancers, 
suggesting an activating and a repressing role on gene expression (78,79). Moreover, accurate 
assignment of an enhancer element to a given gene requires knowledge of long-range 
interactions, based on chromosome conformation capture technology. Therefore, further 
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investigation is needed to understand how and to what extent long-distance transcriptional 
regulation contributes to shape the p53 response. It should also be noted that a small fraction of 
the distal p53 binding sites showed the occurrence of the H3K4me3 mark, suggesting that they 
were erroneously assigned to distal regions and may instead be linked to the promoters of 
unannotated transcripts or ncRNAs. Finally, some of the distal sites didn't bear any of the 
chromatin features investigated so far: more extensive characterization of the chromatin 
signature of these regions may unravel yet unknown aspects of p53 activity.  
 
Fig. 11 - Distribution of p53 peaks at annotated promoters and at distal binding sites. 
Heatmaps showing the distribution of p53 at annotated promoters (panel A) and at distal binding sites 
(panel B). Each row represents a different genomic interval (5 kb width centred on p53 peaks). The 
panels include every annotated promoter and every distant location in chromosome 1 that is identified 
as p53-associated by ChIP-seq in at least one of the experimental samples: unperturbed (mock) and 
irradiated (IR) B cells. For the same intervals, the distribution of H3K4me3, H3K4me1, H3K27ac in B cells 
is shown (157). Genes: RNA transcripts are indicated, based on annotation (exons in red, introns in 
pink; + sense, - antisense strand). 
4.1.2 Expression profiling following acute DNA damage in primary splenic cells.  
We used RNA-Seq to determine total RNA profiles before and after IR exposure. RNA-Seq samples 
were ordered in a dendrogram by unsupervised hierarchical clustering according to similarity in 
gene expression: the shorter the connecting branch, the more similar the expression profiles 
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among the samples (Fig. 12). B and non-B cells were clearly separated in the dendrogram, 
indicating that cell type was the major determinant of expression profiles. Radiation exposure and 
genotype also contributed in shaping the transcriptome: this was particularly evident for B cells, 
which showed very homogeneous profiles, with irradiated and control samples forming distinct 
clusters further sub-divided in clusters of Trp53+/+ and Trp53-/- samples. The result was less clear 
for non-B cells, with higher inter-mixing among genotypes and treatment, possibly owing to the 
heterogeneous composition of this cell population (Fig. 12). We will henceforth concentrate 
mainly on the B cell data. 
 
Fig. 12 - Unsupervised hierarchical clustering of RNA-Seq data identifies the cell type as the major 
determinant of expression profiles. 
Unsupervised hierarchical clustering based on RNA-Seq read counts of all expressed genes (read 
counts>10) in splenic B and non-B cells. Cells were isolated from either control (mock) or irradiated 
animals (IR) 4 hours after γ-radiation. Data are from 4 Trp53 wild-type mice and 2 Trp53 knock-out mice 
in each condition. 
Normalizing the mean expression values of irradiated samples relative to those of unstressed 
controls yielded 3908 and 2123 differentially expressed genes (DEGs) in B and non-B cells, 
respectively (Table 1). In either cell type, approximately half of the DEGs were up- and half down-
regulated. Based upon loss of the response in Trp53 knock-out animals, expression of 1308 and 
1113 up-regulated genes, 476 and 624 down-regulated genes in B and non-B cells, respectively, 
was considered as p53-dependent (Table 1, Fig. 13). Hence, the p53-regulated program 
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constituted a large part of the response to acute DNA damage. p53-dependent and -independent 
genes could be clearly visualized in the scatter plots in Fig. 13, which confronted the fold-change 
values of all DEGs following IR exposure in wild-type cells (x-axis) to Trp53-deficient cells (y-axis). 
In B cells, 54% of the DEGs were p53-independent and formed a neat cloud along the bisector of 
the plot, while the p53-dependent genes grouped separately along the x-axis (Fig. 13A). In non-B 
cells, instead, most DEGs were p53-dependent and the few that were classified as p53-
independent showed smaller fold changes (Fig. 13B). One possible interpretation for this 
observation was that the cell types that constituted the non-B cell population had different p53-
independent responses to IR that opposed each other resulting, on average, in smaller expression 
changes, while retaining similar p53-regulated programs.  
 
Table 1 - Ionizing radiation-regulated genes in B and non-B cells. 
Summary of total numbers and percentages of p53-dependent and -independent IR-regulated genes 
(q-value<0.05; -0.58>log2 of fold-change>0.58) in B and non-B cells, further distinguished in induced 
and repressed genes, and having or not a p53 binding site in the promoter-proximal region containing 
the p53-RE. In case a gene is bound by p53, we analyze the DNA sequence covered by the p53 peak for 
the presence of the p53 motif; in case a gene is not bound by p53, we analyze the DNA sequence from -
600 bp to +400 bp around the TSS, because the promoter-proximal peaks in this setting are on average 
1 kb wide and peak 100 bp upstream of the TSS. p53-dependent genes are defined as follows: all up-
regulated genes in Trp53
+/+
 cells with a fold induction upon IR at least 1.5 times higher than in Trp53
-/-
 
cells and all down-regulated genes in Trp53
+/+
 cells with a fold repression upon IR at least 1.5 times 
lower than in Trp53
-/-
 cells.  
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Fig. 13 - Scatter plot of expression changes following IR in Trp53
+/+
 and Trp53
-/-
 B and non-B cells. 
Scatter plot opposing the log2(FC) (log2 of fold-change) values of all DEGs as estimated by RNA-Seq 
analysis in irradiated B cells (panel A) and non-B cells (panel B) relative to controls in wild-type mice (x-
axis) and the log2(FC) in Trp53-deficient mice (y-axis). Blue dots indicate p53-independent DEGs, red 
dots p53-dependent DEGs.  
Radiation exposure resulted in the activation of programs that were, in part, cell type-specific, as 
already suggested by the hierarchical clustering of the RNA-Seq data (Fig. 12) and as exemplified 
in the plot showing ratios of gene expression changes of all DEGs in B cells (x-axis) versus non-B 
cells (y-axis) (Fig. 14). Thus, many genes were preferentially activated or repressed in one cell type 
or the other, but only a small fraction of genes changed expression in opposite direction in the 
two cell types and with smaller fold changes compared to the rest of the DEGs (Fig. 14). The DEGs 
in common were 32% and 52% of the up-regulated genes, 18% and 41% of the down-regulated in 
B and non-B cells, respectively (Table 2). Of note, p53-dependent genes were the most negatively 
and positively-regulated genes in irradiated B and non-B cells, suggesting that these genes were 
probably the main effectors of the p53 response (Fig. 14). 
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Fig. 14 - Comparison of IR-regulated and p53-dependent genes in B and non-B cells. 
Scatter plot opposing the log2(FC) (log2 of fold-change) values of all DEGs as estimated by RNA-Seq 
analyses in both irradiated B and non-B cells relative to controls. Red dots indicate B cells-specific IR-
regulated DEGs, orange dots B cells-specific IR-regulated and p53-dependent DEGs, blue dots non-B 
cells-specific IR-regulated DEGs, light blue dots non-B cells-specific IR-regulated and p53-dependent 
DEGs. Green dots represent common DEGs between B and non-B cells, with the p53-dependent ones 
colored in dark green. 
To determine which of the IR-regulated genes were direct p53 targets, we combined p53 binding 
and gene expression profiles (Fig. 15). Approximately 30% of the p53-dependent DEGs in either B 
and non-B cells had a p53-binding site nearby the TSS (Table 1, Fig. 15), indicating that most of the 
p53-dependent response was indirectly regulated. We also detected p53 peaks at the promoter of 
p53-independent DEGs, implying that mere p53 binding to the promoter-proximal region of a 
gene was not predictive of transcriptional regulation (Table 1, Fig. 15). Moreover, even though the 
genome-wide p53 DNA-binding patterns were almost identical upon acute DNA damage in B and 
non-B cells (Fig. 7), we observed substantial differences in the transcriptional response to stress, 
further supporting that binding was not predictive of transactivation and implying the 
involvement of other factors, such as cofactors recruited or PTMs of p53, in determining the 
transcriptional outcome in a cell type-specific manner (Fig. 15).  
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Fig. 15 - Heatmap of IR-regulated genes in B and non-B cells together with the indication about 
enrichment of p53 binding at the corresponding promoter. 
Heatmap of the log2(FC) (log2 of fold-change) values of all DEGs (n=4966) as estimated by RNA-Seq 
analyses in both irradiated B and non-B cells relative to controls from Trp53
+/+
 and Trp53
-/-
 animals, 
together with the indication about enrichment of p53 binding at the corresponding promoter (-
600/+400 bp from the TSS). 
To determine whether the transcriptional response correlated with sequence-specific DNA 
binding, we determined the frequency of the p53-RE in the promoters of p53-bound DEGs. To 
correct for the probability of identifying the p53 motif by chance, we analyzed the DNA sequence 
of the promoter region (-600 bp to +400 bp from the TSS) of the DEGs not bound by p53 as 
negative control (Table 1). Remarkably, the motif was significantly enriched among 40% of the 
p53-dependent up-regulated genes compared to less than 5% of the unbound ones, but not 
among the p53-dependent down-regulated genes (Table 1), indicating that only gene induction, 
but not gene repression, was directly regulated by p53 via binding to the p53-RE.  
We tested whether p53 binding on the p53-RE nearby the TSS of a gene would be predictive of 
gene transactivation: we observed that the percentage of up-regulated p53-bound genes 
increased from 5-10% of induced genes, when we considered any gene with a p53 binding site 
nearby the TSS, to 20-30%, when we analyzed only genes with a p53 peak on the p53-RE (Fig. 16). 
Moreover, more than 80% of the DEGs bound by p53 on the p53-RE were also p53-dependent, 
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suggesting that p53 regulated the expression of the genes that it directly bound. Differently from 
other transcription factors, such as Myc, p53 didn't bind the RE at the promoter of genes that 
were not under its direct control. The remaining direct p53 targets containing the p53 motif may 
not increase significantly the transcript levels at this time point or require other factors for their 
regulation (Fig. 16). 
 
Fig. 16 - Expression changes of p53-bound genes following IR. 
Bar plot showing the percentage and the absolute number of all p53-bound genes and of p53-bound 
genes containing the p53-RE in irradiated (IR) B and non-B cells that don't change expression (black 
bar), or that are up-regulated (red bar) or down-regulated (blue bar) in response to DNA damage in a 
p53-dependent or -independent way, as indicated. 
To gain more insights into how p53 regulated transcription, we inspected p53 binding strength in 
the promoter-proximal regions (Fig. 17). As previously observed (Fig. 10), higher p53 binding 
strength correlated with the presence of the p53-RE. However, among the binding sites on the 
p53 motif, the peak enrichment of those at the promoter of up-regulated genes was significantly 
higher compared to genes that didn't change their expression in response to acute DNA damage 
(p-value: 4 x 10-9 in B cells, 2 x 10-6 in non-B cells). This correlation was not observed or less 
significant when we compared p53-bound genes without the p53 motif. Altogether p53 binding 
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strength, like the presence of the p53 motif, correlated with gene activation. Furthermore, we 
could speculate that the genes bound by p53 at the p53-RE that were not identified as 
differentially expressed in response to DNA damage, may instead be activated in a minor fraction 
of cells, as indicated by the lower peak enrichment, therefore resulting on average as not having 
changed expression. It would be worth measuring the differential expression of these genes at a 
later time points, to check if their steady state mRNA levels would increase. 
 
Fig. 17 - Higher p53 binding intensities are most frequently correlated with transcriptional activation. 
Box plots showing the enrichment of p53 peaks in irradiated (IR) B cells (panel A) and non-B cells (panel 
B) in the promoter region of genes containing or not the p53-RE, as indicated. Black box, no DEG no p53 
motif present; grey box, no DEG p53 motif present; blue box, down-regulated p53-independent genes 
no p53 motif present; light blue box, down-regulated p53-dependent genes no p53 motif present; red 
box, up-regulated p53-independent genes no p53 motif present; orange box, up-regulated p53-
dependent genes no p53 motif present; seagreen box, up-regulated p53-dependent genes p53 motif 
present. The boxes are drawn with widths proportional to the square-roots of the number of 
observations in the groups. 
The p53-dependent IR-induced genes constituted the gene set with the highest percentage of 
common DEGs between B and non-B cells: this overlap increased when we restricted the analysis 
to the p53-bound ones, and even more when we considered only the subset containing the p53-
RE, with almost 90% of the p53-dependent up-regulated genes containing the p53 consensus 
motif in non-B cells identified in B cells, as well (Table 2). Closer inspection of these gene lists 
indicated that some genes were defined as p53-dependent in one cell type but not in the other, 
indicating that some bona fide p53 targets may be missed in this analysis due to the stringency of 
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our statistical criteria. Altogether these data suggested that directly induced p53 targets 
constituted the core of a cell type-independent p53 response. The comparison between p53-
independent genes was limited by the fact that they were very few in non-B cells. 
 
Table 2 - Overlap of ionizing radiation-regulated genes in B and non-B cells. 
Summary of total numbers of induced and repressed IR-regulated genes, further distinguished in p53-
dependent and p53-independent, and in p53-bound and -unbound and containing the p53-RE. The 
number and the percentage of common genes between B and non-B cells in the different categories is 
reported. 
A biological process Gene Ontology (GO) analysis indicated that the direct p53 targets containing 
the p53-RE were involved in the negative regulation of cell cycle progression and in the apoptotic 
and DNA damage response (Fig. 18). The down-regulated p53-dependent genes, whether p53-
bound or not, enriched for terms related to cell cycle and mitosis (Fig. 18). p53 was named the 
'guardian of the genome' for the ability of transiently blocking cell cycle progression in response 
to genotoxic stress, allowing cells to repair their genome before proceeding to cell division, and 
thereby preventing the accumulation of mutations. In case the DNA alteration was not corrected, 
p53 signaled the cells to undergo apoptosis. The up-regulated genes not bound by p53 enriched 
for categories associated to tissue development, organ morphogenesis and cell-cell signaling in 
either B and non-B cells, in ion transport in the B cells only, in locomotion and response to 
external stimulus in the non-B cells only (Fig. 18). 
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Fig. 18 - Functional annotation of IR-regulated p53-dependent DEGs. 
Gene Ontology terms enriched in up- and down-regulated p53-dependent genes in B and non-B cells 
following IR exposure relative to controls, further distinguished in p53-bound and -unbound and 
containing the p53-RE. GO terms significantly enriched (Fisher test p-value<1*10
-5
) in at least one gene 
set were selected (rows in the heatmap) and the p-values for each GO term in each gene set (columns) 
were colour-coded as indicated. Only GO terms in the biological process ontology that are assigned to 
less than 2,000 and more than 10 genes in the mouse genome are considered.  
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Distinct transcription factors may contribute to the IR response, in particular to the regulation of 
those p53-dependent genes that were not bound by p53, or were bound by p53 but in the 
absence of the canonical motif. To address this issue, we performed a de novo motif search using 
MEME-ChIP (151). Confirmation of the accuracy of our analysis came from the identification of 
the canonical p53 motif at the binding sites on the p53-RE (Table 3). Among the other motifs 
identified there were potential binding sites for Sp1 and Sp2, Egr1 (early growth response protein 
1), FoxP1 (Forkhead box protein P1), Nfy (nuclear transcription factor Y), Klf (Krüppel-like factors), 
and several others (Table 3). Some of these factors were previously suggested to cooperate with 
p53 (74,158), however our motif analysis of random promoters and of the promoters of p53-
independent genes indicated that the results were biased towards commonly identified binding 
sites in the TSS-proximal region and didn't highlight p53-specific effectors, whose recognition 
motif could have been hidden by the abundance of binding sites for more general transcriptional 
regulators.  
 
 
Table 3 - Overrepresented transcription factor binding motifs at the promoter of p53-dependent and -
independent genes. 
De novo motif search by MEME-ChIP (151): the top motif (lowest E-value) are depicted. In case a gene 
is bound by p53, we analyze the DNA sequence covered by the p53 peak; in case a gene is not bound by 
p53, we analyze the DNA sequence from -600 bp to +400 bp around the TSS. The analysis of 500 
randomly selected promoters is included as negative control. 
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As de novo motif search highlighted very general transcription factor binding motifs; we used 
Ingenuity Pathway Analysis (IPA), to identify regulators that could mediate indirect gene 
regulation downstream of p53 activation: this analysis pointed to the microRNA let-7, the E2f 
family of transcription factors (in particular E2f4), the cell cycle inhibitor and well-known p53 
target p21 (Cdkn1a), cyclin D1 (Ccnd1), the cyclin-dependent kinase 4 (Cdk4) and the 
retinoblastoma protein (Rb) as possible regulators of the p53-dependent IR-repressed genes, 
whether p53-bound or not, and in either B- and non-B cells (Table 4). All these factors, except let-
7, act in the same pathway: while the cyclin D-Cdk4 complex mediates Rb phosphorylation, p21 
inhibits it. Unphosphorylated Rb is inactive and cannot dissociate from E2f, resulting in the 
repression of E2f-regulated cell cycle genes. Hence, in agreement with published findings, gene 
repression in our experimental model appeared to be indirect, and likely mediated by the 
microRNA let-7 and by p53-mediated induction of p21, and consequent repression of the Rb/E2f 
axis (85,159). 
 
Table 4 - Putative upstream regulators of p53-dependent down-regulated genes. 
IPA Upstream Regulator Analysis of p53-dependent down-regulated genes having or not a p53 binding 
site at the promoter. Statistical significance and p-values are determined by IPA using a Fisher's Exact 
Test.  
p53, its family members p63 and p73 and its cofactor Brd7 (160), were identified as the main 
regulators of the p53-dependent up-regulated genes that had a p53 binding site on the p53-RE 
nearby the TSS in either B- and non-B cells (Table 5). p53 and NF-κB were indicated as regulators 
of the induced p53-dependent genes bound by p53 in the absence of the canonical motif, 
highlighting a pathway that was previously described to be important for the induction of 
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apoptosis (161) (Table 5). Finally, the putative regulators of the non p53-bound genes were 
different in B and non-B cells. Of note, none of the regulators identified for the p53-dependent 
genes was also indicated for the p53-independent genes, suggesting that these downstream 
effectors were specific to the p53 response (Table 6). However, we didn't identify any direct p53 
target containing the p53-RE that could mediate gene activation, as p21 for gene repression. 
 
Table 5 - Putative upstream regulators of p53-dependent up-regulated genes. 
IPA Upstream Regulator Analysis of p53-dependent up-regulated genes having or not a p53 binding site 
at the promoter containing the p53-RE. Statistical significance and p-values are determined by IPA 
using a Fisher's Exact Test.  
 
Table 6 - Putative upstream regulators of p53-independent genes in B cells. 
IPA Upstream Regulator Analysis of p53-independent up-and down-regulated genes in B cells having or 
not a p53 binding site at the promoter. Statistical significance and p-values are determined by IPA using 
a Fisher's Exact Test. The limited number of p53-independent genes in non-B cells prevented the 
analysis.  
60 
 
In conclusion, our observations could be summarized in the following model: upon acute DNA 
damage, p53 binds, in a selective way, the p53-REs in the genome and induces the transcription of 
several p53 effectors, which then extend the p53-dependent network in a cell type-specific way; 
moreover, it up-regulates p21 and indirectly let-7, which then mediate repression of cell cycle 
genes (Fig. 19). 
 
Fig. 19 - Model of p53-mediated gene regulation. 
4.1.3 p53 in unperturbed conditions 
Under normal unperturbed conditions, p53 is a very unstable protein with a half life of 5-20 
minutes (162), therefore it was relatively surprising to detect it bound to chromatin in vivo, in cells 
fixed immediately after purification from the spleen. Previous studies had reported p53-DNA 
interactions in unstressed cells; however, they were all performed in immortalized cancer cell 
lines or upon prolonged culturing in vitro, conditions that are known to activate p53 (69,78,82). 
Recently, El-Dahr and coworkers described the p53-regulated program in developing mouse 
kidney, demonstrating a role for p53 in a physiological process, such as organ development (83).  
We previously showed that, in B cells, p53 affected the expression profile not only following IR 
exposure, but also in unperturbed conditions (Fig. 12). To identify the biological processes 
regulated by p53 at basal levels, we searched for genes differentially expressed between 
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unstressed Trp53+/+ and Trp53-/- B cells. We identified 296 genes, with a median of fold induction 
of 1.5 (Fig. 20). A biological process Gene Ontology (GO) analysis on these basal p53-regulated 
genes most significantly enriched for terms related to regulation of cellular component size, in 
particular membrane and cytoskeleton organization, Ras signalling and amino acid import (Table 
7). We analyzed published RNA-Seq data (69) using the same parameters as for our analysis and 
observed that 38% of these basal regulated genes were differentially expressed between Trp53+/+ 
and Trp53-/- mouse embryonic fibroblasts (MEFs), suggesting that, at least in part, this was not a 
cell type-specific program. Of note, only four of the basal regulated genes (Pla2g4a, Trpm2, 
Slc39a9, 9030617O03Rik) were bound by p53 in unstressed conditions. As previously observed in 
MEFs, we confirmed that this basal p53 program was mainly indirectly regulated. 
 
Fig. 20 - Differential expression of basal p53-regulated genes between unstressed Trp53
+/+
 and  
Trp53
-/-
 B cells.  
Box plot showing the log2(FC) (log2 of fold-change) values of basal p53-regulated genes in Trp53
+/+
 
relative to Trp53
-/-
 unstressed B cells. 
 
Table 7 - Functional annotation of p53 basal regulated genes in B cells. 
Biological process GO terms enriched in the list of genes differentially regulated between unstressed 
Trp53
+/+
 and Trp53
-/-
 B cells, with p-values as calculated by DAVID (154,155) using a modified Fisher 
exact test. 
Since the basal regulated genes were not direct p53 targets, we performed a biological process 
GO analysis on the gene set bound by p53 in unstressed cells to understand its function. The p53-
bound genes in unperturbed B and non-B cells enriched for multiple terms related to leukocyte 
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activation and regulation of immune response, and for cell type-specific categories like B 
lymphocytes activation in B cells and granulocyte, T cell and myeloid cell differentiation in non-B 
cells (Fig. 21). 
 
Fig. 21 - p53 binding sites in unperturbed cells are associated with genes involved in immune cell 
activation and cell type-specific functions. 
Biological process GO terms enriched in p53-bound genes in unstressed B and non-B cells, with 
binomial p-values as calculated by GREAT (156). 
To test if p53 was poised for activation on these basally bound genes, we checked whether they 
changed their expression following IR. Approximately 10% of these genes became differentially 
expressed both in B and non-B cells following IR exposure, and the percentage increased to 30-
40% when we considered only the binding sites containing the p53 motif (Fig. 22). p53 seemed to 
be poised for activation at its response elements, in the absence of stress stimuli, on cell type-
specific genes involved in basic cellular functions, ready to be triggered by PTMs or the 
recruitment of cofactors to direct a fast response to the insult.  
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Fig. 22 - Expression changes of p53-bound genes in control samples following IR. 
Bar plot showing the percentage of p53-bound genes in unperturbed (mock) B cells and non-B cells that 
don't change expression (black bar), or that are up-regulated (red bar) or down-regulated (blue bar) in 
response to DNA damage in a p53-dependent or -independent way, as indicated. 
4.2 Characterization of the p53-dependent response to Myc oncogenic stress 
In the literature, there are numerous evidences of the fundamental role played by p53 in 
preventing cancer development; nevertheless, how p53 regulates tumor suppressive programs is 
still not completely understood. To gain more insight into this process, we generated whole 
genome maps of p53 binding and gene expression profiles during tumor progression in Eμ-myc 
transgenic mice, as well as during the regression of Myc-driven lymphomas following restoration 
of p53 function, by either pharmacological or genetic means.  
4.2.1 Eμ-myc pre-tumoral mice 
The Eμ-myc mouse model is characterized by a temporally defined pre-tumoral phase, during 
which the high rates of cell divisions driven by Myc are counter-balanced by the activation of 
intrinsic tumor suppressive mechanisms that effectively restrain clonal expansion of pre-
cancerous cells: the major compensatory mechanism triggered by oncogenic Myc in this setting is 
apoptosis (128,129), but evidence emerged for a contribution of senescence (130,131). 
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Remarkably, both of these responses are mediated by p53, and loss of p53 activity is the major 
selected event in lymphomagenesis (126,127). 
To dissect the p53-dependent program during tumor development, we generated ChIP-seq 
profiles in B cells from young non-transgenic (control, C) and Eμ-myc transgenic littermates (pre-
tumoral, P): this yielded around 230 peaks both in C and in P, of which 80% were identified in 
both samples. p53 binding intensity increased from C to P, indicating that a bigger fraction of cells 
had p53 bound to those genomic regions in P (Fig. 23). Half of the binding sites were at distal 
intergenic loci, and the remaining ones were distributed between promoters and gene bodies 
(Fig. 24). Approximately, half of the peaks both in C and P enriched for the p53 consensus motif 
(Fig. 23, Fig. 24). 
 
Fig. 23 - Heatmap of p53 binding sites in control and pre-tumoral B cells. 
Heatmaps showing library size-normalized ChIP-seq read counts for all p53-bound promoters (-5/+2 kb 
from the TSS), gene bodies (+2 kb from the TSS through 3'UTR) and intergenic regions (everything else) 
in control (C) and Eμ-myc pre-tumoral (P) B cells. Peaks are ranked from top to bottom by reads density 
in sample C. The occurrence of the p53 motif at the genomic intervals analyzed is calculated by the 
FIMO algorithm (153) (p-value<1 x 10
-5
) and indicated with blue lines on the right side of the heatmaps. 
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Fig. 24 - Motif analysis and genomic distribution of p53-binding sites in control and pre-tumoral B 
cells.  
Characterization of all p53-bound sites at promoters (-5/+2 kb from the TSS, red bar), gene bodies (+2 
kb from the TSS through 3'UTR, green bar) and intergenic regions (everything else, blue bar) in control 
(C) and Eμ-myc pre-tumoral (P) B cells, for the occurrence of the p53 motif as calculated by the FIMO 
algorithm (p-value<1 x 10
-5
). The percentage of p53-bound sites containing the p53-RE is reported. 
The readers may have noticed that in control B cells from C57/Bl6 mice in our irradiation 
experiments (Fig. 7) we identified 10-times more peaks than in control B cells from non-transgenic 
mice of the Eμ-myc cohort (C). To test if these two mouse strains would respond differently to a 
genotoxic insult, we profiled RNA expression in non-transgenic mice of the Eμ-myc cohort before 
and four hours after exposure to 7 Gy whole-body irradiation and compared the RNA-Seq read 
counts for all genes obtained in the two mouse strains. We observed a very high correlation of 
gene expression (Fig. 25). Hence, despite a different p53 binding pattern in control cells, the 
transcriptional response to stress was substantially identical between the two mouse strains. We 
surmise that basal p53 activity can vary between mouse cohorts of similar genetic background, 
highlighting the sensitivity of p53 to subtle genetic and/or environmental cues, which remain to 
be characterized. 
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Fig. 25 - The transcriptional profiles in B cells from control and irradiated C57/Bl6 and Eμ-myc C mice 
are substantially identical. 
Scatter plot of library size normalized RNA-Seq read counts for all annotated genes in B cells from 
control (mock) and irradiated (IR) C57/Bl6 mice and non-transgenic mice of the Eμ-myc cohort (C). The 
correlation coefficient is reported on the graphs. 
4.2.2 p53 restoration in Eμ-myc lymphomas (i.): p53ERTAM knock-in 
The p53 pathway is impaired in tumors, but its reinstatement has been shown to induce tumor 
regression (136,139,140). Here, we characterized the cellular and transcriptional responses 
induced upon p53 restoration in lymphomas arising from Eμ-myc mice heterozygous for a knock-
in allele expressing the conditional p53ERTAM fusion protein (Eμ-myc p53ERTAM) (136). 
Administration of tamoxifen (TAM) in vivo allowed a fast transition from a p53 null state to a 
functional p53 state; once activated, p53 became competent to sense pre-existing stimuli and 
mount a response. Eμ-myc p53ERTAM mice developed lymphomas by 50 days of age; the 
lymphomas were collected, serially transplanted into syngeneic mice and allowed to develop in 
the absence of tamoxifen. When the tumors were palpable, p53ERTAM was activated by 
intraperitoneal injection of 1 mg of tamoxifen, triggering rapid and massive apoptosis of the 
lymphoma cells (measured as sub-G1 fraction) (Fig. 26). The expression of known p53 target 
genes increased 2.5 hours after tamoxifen administration, preceding the increase in apoptosis 
(Fig. 26, Fig. 27). 
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Fig. 26 - p53 restoration in Eμ-myc p53ER
TAM
 lymphomas in vivo triggers rapid apoptosis. 
Representative flow cytometric analysis of DNA content (PI staining) of Eμ-myc p53ER
TAM
 lymphoma 
cells harvested at different time points after vehicle or TAM injection. 
 
Fig. 27 - p53 restoration in Eμ-myc p53ER
TAM
 lymphomas in vivo induces the expression of p53 target 
genes. 
The expression of p53 target genes (Cdkn1a/p21, Pmaip1/Noxa, Bbc3/Puma) is measured by real-time 
PCR 2.5 hr after TAM or vehicle in vivo treatment in four different Eμ-myc p53ER
TAM
 lymphomas. 
A similar response was observed when p53ERTAM was reactivated in vitro in cultured lymphomas, 
with cell death starting 4 hours after p53 restoration (Fig. 28). For in vitro analyses, we chose to 
treat the lymphoma cells for 2 hours with 4-OHT: at this time point we could measure an 
induction in p53 target genes (Fig. 29) with no substantial increase in apoptosis above the basal 
levels seen in untreated cells (Fig. 28).  
 
Fig. 28 - p53 restoration in Eμ-myc p53ER
TAM
 lymphomas in vitro triggers rapid apoptosis. 
Percentage of dead cells measured by Trypan blue assay was reported at each time point for 100 nM 4-
OHT- and vehicle-treated Eμ-myc p53ER
TAM
 lymphoma cells. 
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Fig. 29 - p53 restoration in Eμ-myc p53ER
TAM
 lymphomas in vitro induces the expression of p53 target 
genes. 
The expression of p53 target genes (Cdkn1a/p21, Pmaip1/Noxa, Bbc3/Puma) is measured by real-time 
RT-PCR 2 hr after 100 nM 4-OHT or vehicle in vitro treatment in four different Eμ-myc p53ER
TAM
 
lymphomas. 
As assayed by ChIP, the p53ERTAM chimera was a bit leaky: we could detect p53-DNA interactions 
slightly above background already in vehicle-treated cells, which then increased upon p53 
restoration by 4-OHT treatment (Fig. 30).  
 
Fig. 30 - ChIP-qPCR analysis of p53 binding. 
qPCR analysis of p53 ChIP in four 100 nM 4-OHT- or vehicle-treated Eμ-myc p53ER
TAM
 lymphomas at the 
promoters of two known p53 target genes Cdkn1a/p21 and Bbc3/Puma. Acetylcholine receptor is 
analyzed as a negative control. ChIP data are quantified as percentage of input DNA. 
We performed p53 ChIP-sequencing in four Eμ-myc p53ERTAM lymphomas upon p53 restoration by 
4-OHT treatment in vitro in cultured lymphomas and in vivo by TAM injection in mice with 
palpable tumors (Fig. 31). The in vivo restoration samples had narrower peaks because of 
technical problems that resulted in lower sequencing depth. Nonetheless, the promoter-proximal 
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and distal binding sites with the highest enrichment levels in the in vitro treated samples were 
also identified upon in vivo restoration of p53. In the in vivo data we identified more distal sites, 
not observed in the in vitro data, that were also only partially overlapping between the different 
lymphomas (Fig. 31B). Since the sequencing quality of the in vitro data was better and the other 
experiments of p53 reinstatement were performed on cultured lymphomas (see below), we 
continued the analysis only on the in vitro data. 
 
Fig. 31 - Distribution of p53 peaks at annotated promoters and at distal binding sites upon p53 
restoration in vivo and in vitro in Eμ-myc p53ER
TAM
 lymphomas. 
Heatmaps showing the distribution of p53 at annotated promoters (panel A) and at distal binding sites 
(panel B) in four Eμ-myc p53ER
TAM
 lymphomas (T) treated in vitro with 100 nm 4-OHT or in vivo with 1 
mg of TAM. Each row represents a different genomic interval (4 kb width centred on p53 peaks). The 
panels include every annotated promoter and every distant location at chromosome 1 that is identified 
as p53-associated by ChIP-seq in at least one of the experimental samples. Annotated genes (exons in 
red, introns in pink; + sense, - antisense strand) are also shown. 
We observed that both the binding intensity and total number of binding sites increased upon 
p53 restoration, reaching up to 3500 p53 peaks in lymphomas 1 and 2, 9000 and 8000 in 
lymphomas 3 and 4, respectively (Fig. 32, Fig. 33). The binding sites with the highest enrichment 
levels were identified in all tumors and most of the weaker ones were retrieved in at least two 
samples, confirming their specificity (Fig. 33). In all the lymphomas, the binding sites at promoter-
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proximal regions were the most abundant, but only around 10% contained the canonical p53-RE 
(Fig. 34). Moreover, most of the new p53 binding sites identified only in lymphomas 3 and 4 were 
located at annotated promoters and few in distant regions (Fig. 31, Fig. 32). Distal binding sites 
were around 3000 to 4000 in the different lymphomas and approximately one third of these sites 
had a p53 consensus motif. As previously observed in B and non-B cells, binding to the p53-RE 
correlated with higher peak enrichment (Fig. 35). 
 
Fig. 32 - Heatmaps of p53 binding sites in vehicle- and 4-OHT-treated Eμ-myc p53ER
TAM
 lymphomas. 
Heatmaps showing library size-normalized ChIP-seq read counts for all p53-bound promoters (-5/+2 kb 
from the TSS), gene bodies (+2 kb from the TSS through 3'UTR) and intergenic regions (everything else) 
at chromosome 1 in control and 4-OHT-treated Eμ-myc p53ER
TAM
 lymphoma cells (T). Peaks are 
hierarchically clustered. The occurrence of the p53 motif at the genomic intervals analyzed is calculated 
by the FIMO algorithm (153) (p-value<1 x 10
-5
) and indicated with blue lines on the right side of the 
heatmaps. 
 
Fig. 33 - Overlap of p53 binding sites between four 4-OHT-treated Eμ-myc p53ER
TAM
 lymphomas. 
Venn diagrams of p53 binding sites in four 4-OHT-treated Eμ-myc p53ER
TAM
 lymphoma cells (T). 
Percentages indicate the number of peaks for each lymphoma present in at least another sample. 
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Fig. 34 - Motif analysis and genomic distribution of p53-binding sites in vehicle- and 4-OHT-treated 
Eμ-myc p53ER
TAM
 lymphomas. 
Characterization of all p53-bound sites at promoters (-5/+2 kb from the TSS, red bar), gene bodies (+2 
kb from the TSS through 3'UTR, green bar) and intergenic regions (everything else, blue bar) in control 
and 4-OHT-treated Eμ-myc p53ER
TAM
 lymphoma cells (T), for the occurrence of the p53 motif as 
calculated by the FIMO algorithm (p-value<1 x 10
-5
). The percentage of p53-bound sites containing the 
p53-RE is reported. 
 
Fig. 35 - Stronger p53 binding sites are more likely to contain the consensus p53 motif. 
Peak enrichment of p53 binding sites that contain (grey boxes) or not (black boxes) the p53 motif in 
control (EtOH) and 100 nM 4-OHT treated Eμ-myc p53ER
TAM
 lymphoma cells (T). 
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4.2.3 p53 restoration in Eμ-myc lymphomas (ii.): LSL-p53 
As a second model of tumor regression, we generated tumors carrying a reactivatable Trp53 allele 
by crossing Eμ-myc mice with LSL-p53 mice (139). The LSL-p53 mice carry a transcription–
translation stop cassette flanked by loxP sites (LSL) in the first intron of the wild-type Trp53 locus. 
The STOP element efficiently silences Trp53 expression and can be excised by Cre recombinase, 
thus restoring the expression of the endogenous Trp53 gene. Eμ-myc mice heterozygous for LSL-
p53 developed lymphomas by 35 days of age, with every lymphoma analyzed showing loss of 
heterozygosity (LOH) for the wild-type Trp53 allele (Fig. 38), as expected according to previous 
observation in Eµ–myc lymphomas arising in Trp53+/− animals (126,127). To temporally control 
p53 reactivation, we infected lymphoma cells with a selectable retroviral vector expressing a Cre-
recombinase-Estrogen-Receptor-T2 (Cre-ERT2) fusion protein (146). The ERT2 moiety caused 
retention of the Cre recombinase in an inactive form in the cytoplasm until tamoxifen 
administration released this inhibition, thus permitting the recombination of the genomic loxP 
sites. Release of the transcription–translation block by provision of tamoxifen did not itself 
activate p53 but simply restored the expression of the wild-type p53 protein which was then 
competent to become activated by appropriate signals in the cell, in this particular case by Myc-
induced oncogenic stress and elevated levels of p19Arf (116,126). 
The STOP element efficiently prevented gene expression, with no detectable p53 mRNA or 
protein in vehicle-treated cells (Fig. 36, Fig. 37). Trp53 mRNA levels peaked eight hours after Cre 
activation by 4-OHT treatment, along with the mRNAs of two well-known p53 targets Cdkn1a and 
Bbc3 (Fig. 36). Western blot analysis showed accumulation of the p53 protein (Fig. 37) and 
excision of the STOP element, even though incomplete, was also detected by PCR on genomic 
DNA (Fig. 38). Restoration of p53 function selected for the rapid outgrowth of undeleted clones, 
as indicated by the decrease in the intensity of the band of the recombined LSL cassette over time 
after Cre activation. The presence of undeleted clones together with the fact that recombination 
of the LSL casette was not synchronous in all cells, causing that the cells that recombined first 
were lost by apoptosis before the others started to recombine the locus, prevented the detection 
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of cell death that was instead observed in Eμ-myc p53ERTAM lymphomas. For these reasons, the 
analysis of p53-dependent responses was confined within 8 hours. 
 
Fig. 36 - Conditional reactivation of p53 in vitro in Eμ-myc LSL-p53 lymphomas induces the expression 
of p53 target genes. 
Real time RT-PCR analysis shows induction of expression of Trp53 and p53 target genes Cdkn1a/p21 
and Bbc3/Puma in five different Eμ-myc LSL-p53 lymphomas (T) at different time points after in vitro 
treatment with 250 nM 4-OHT or vehicle. 
 
Fig. 37 - Western blot analysis of the p53 protein in Eμ-myc LSL-p53 lymphomas. 
p53 stabilization is determined by quantitative infrared Western blotting in five different Eμ-myc LSL-
p53 lymphomas (T) 8h after in vitro treatment with 250nM 4-OHT or vehicle. Densitometric 
quantification of p53 band is shown normalized to vinculin. 
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Fig. 38 - Excision of the STOP element in Eμ-myc LSL-p53 lymphomas. 
Excision of the STOP element is determined by PCR on genomic DNA from five different Eμ-myc 
lymphomas (T) treated in vitro with 250 nM 4-OHT or vehicle using the same amount of starting 
material. Tail DNA from a LSL-p53 heterozygous mouse is included as positive control. Genotyping by 
PCR amplification of matched normal tail DNA (M) shows that Eμ-myc LSL-p53 tumors undergo LOH of 
the wild-type Trp53 allele. 
We analyzed the genomic distribution of p53 in three Eμ-myc LSL-p53 lymphomas eight hours 
after Cre activation by 4-OHT treatment. In vehicle-treated cells, we could identify very few peaks 
throughout the whole genome, likely false positive hits since they constituted the only few sites 
not overlapping the p53 consensus motif (Fig. 39). This evidence confirmed the efficiency of the 
STOP element in blocking Trp53 expression and the specificity of the antibody in detecting p53. 
Upon 4-OHT-treatment, we detected around 1000 to 2000 p53 binding sites in the different 
lymphomas. Lymphoma 2 had the lowest number of p53 peaks, which constituted a fraction of 
the peaks in lymphoma 3 that in turn represented a fraction of the peaks in lymphoma 1 (Fig. 39, 
Fig. 40), correlating with the relative levels of p53 achieved in each of those lymphomas. p53 
peaks in lymphoma 2 constituted the binding sites with the highest levels of enrichment in the 
other two lymphomas, suggesting that in this sample our sensivity in the detection of p53-DNA 
interactions was lower and therefore we identified only the high affinity sites. 90% of all binding 
sites overlapped with the p53-RE and approximately 60% were at intergenic sites, 30% at gene 
bodies and 10% at promoters. Differently from the Eμ-myc p53ERTAM lymphomas, where we 
identified up to 9000 p53 binding sites, in Eμ-myc LSL-p53 lymphomas we detected fewer binding 
sites, but which all contained the p53-RE. Thus, in this experimental setting, we identified only the 
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high affinity p53 binding sites because our sensitivity in calling the peaks was decreased by the 
presence of undeleted clones. 
 
Fig. 39 - Heatmaps of p53 binding sites in vehicle- and 4-OHT-treated Eμ-myc LSL-p53 lymphomas. 
Heatmaps showing library size-normalized ChIP-seq read counts for all p53-bound sites at promoters (-
5/+2 kb from the TSS), gene bodies (+2 kb from the TSS through 3'UTR) and intergenic regions 
(everything else) in control and 4-OHT-treated Eμ-myc LSL-p53 lymphoma cells (T). Peaks are 
hierarchically clustered. The occurrence of the p53 motif at the genomic intervals analyzed is calculated 
by the FIMO algorithm (153) (p-value<1 x 10
-5
) and indicated with blue lines on the right side of the 
heatmaps. 
 
Fig. 40 - Overlap of p53 binding sites in three Eμ-myc LSL-p53lymphomas. 
Venn diagram of p53 binding sites in 4-OHT-treated Eμ-myc LSL-p53 lymphoma cells (T). Percentages 
indicate the number of peaks for each lymphoma present in at least another sample. 
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Fig. 41 - Motif analysis and genomic distribution of p53-binding sites in 4-OHT-treated Eμ-myc LSL-
p53 lymphomas. 
Characterization of all p53-bound sites at promoters (-5/+2 kb from the TSS, red bar), gene bodies (+2 
kb from the TSS through 3'UTR, green bar) and intergenic regions (everything else, blue bar) in 4-OHT-
treated Eμ-myc LSL-p53 lymphoma cells (T), for the occurrence of the p53 motif as calculated by the 
FIMO algorithm (p-value<1 x 10
-5
). The percentage of p53-bound sites containing the p53-RE is 
reported. 
4.2.4 p53 restoration in Eμ-myc lymphomas (iiI.): small molecules 
Restoring p53 function in tumor cells is an attractive strategy in cancer therapy. In the clinic, this 
can be achieved using small molecules to reactivate wild-type p53, when present in tumors. This 
is the case, for example, in Eμ-myc Arf-/- Trp53+/+ lymphomas, in which loss of Arf leads to 
enhanced degradation of p53, thereby alleviating the selective pressure to mutate the Trp53 
gene. Indeed, Eμ-myc Arf-/- Trp53+/+ lymphomas spontaneously arise by LOH at the Arf locus in Eμ-
myc Arf heterozygous mice (126,127). Therefore, as a third model of tumor regression, we 
investigated p53-dependent transcriptional responses induced in Eμ-myc Arf-/- Trp53+/+ 
lymphomas following treatment with doxorubicin (also known as adriamycin), a genotoxic drug 
that triggers p53 activity, or Nutlin, a non-genotoxic molecule that interferes with the ability of 
Mdm2 to target p53 for degradation (163). Nutlin is a chiral molecule: (-)-Nutlin is 150 times more 
potent in binding Mdm2 than (+)-Nutlin (163). We thus decided to use the inactive enantiomer as 
a control for off-target effects.  
We performed a time-course experiment to determine the best time point for our analysis. We 
observed that between three and four hours of treatment in vitro with both doxorubicin and (-)-
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Nutlin cells stopped proliferating and started to die, correlating with p53 protein stabilization (Fig. 
42, Fig. 43, Fig. 44, Fig. 45). Both compounds induced apoptosis of all lymphoma cells within 
twenty-four hours after treatment (data not shown). We chose to analyze the three hours time 
point because we could detect clear accumulation of the p53 protein, with no substantial 
induction of apoptosis. 
 
Fig. 42 - Four hours after drug exposure Eμ-myc Arf
-/- 
Trp53
+/+
 lymphoma cells stop proliferating. 
The average percent of G1-, S-, G2-phase cells from three Eμ-myc Arf
-/-
 Trp53
+/+ 
lymphomas treated with 
1µM doxorubicin, 5µM (-)-Nutlin or vehicle is shown in a time-course experiment of cell cycle analysis 
by PI staining.  
 
Fig. 43 - Between three and four hours after drug exposure, lymphoma cells stop proliferating. 
Representative DNA content profile is shown. 
 
Fig. 44 - Four hours after drug exposure, cells start to die.  
Time-course of accumulation of cells with sub-G1 DNA content in three Eμ-myc Arf
-/-
 Trp53
+/+ 
lymphomas treated with 1µM doxorubicin, 5µM (-)-Nutlin or vehicle. 
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Fig. 45 - Time-course of p53 stabilization following drug exposure. 
p53 stabilization is determined by quantitative infrared Western blotting. Densitometric quantification 
of p53 band is shown normalized to vinculin. 
Previous published work stated that dimethylsulphoxide (DMSO), the solvent used to solubilize 
Nutlin, induced p53 binding to many sites (62), therefore we tested different conditions to choose 
the right controls for ChIP-Seq and RNA-Seq analysis. We observed that treatment with DMSO, 
H2O or (+)-Nutlin didn't affect the p53 binding profile compared to untreated control, except for 
minor differences due to technical variability (Fig. 46), therefore the choice of one was equal to 
the other.  
 
Fig. 46 - Heatmap of p53 binding sites in unperturbed Eμ-myc Arf
-/-
 Trp53
+/+
 lymphomas. 
Heatmap showing library size-normalized ChIP-seq read counts for p53-bound genomic regions at 
chromosome 1, in three Eμ-myc Arf
-/-
 Trp53
+/+ 
lymphomas cells (T) left untreated (NT) or treated for 3 
hr with 0.1% H2O, 0.05% DMSO or 5µM (+)-Nutlin. Peaks are hierarchically clustered. 
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Both (-)-Nutlin and doxorubicin treatment increased p53 chromatin occupancy and induced 
similar p53 binding profiles between the different lymphomas and to the ones triggered by the 
other drug, implying common features between these two different modes of activating p53 (Fig. 
47, Fig. 48). All the peaks identified in control samples were present in the treated samples and 
were among the strongest binding sites (Fig. 47). Approximately 50-60% of the peaks identified 
upon p53 activation by small molecules were located in the promoter-proximal region, but only 
10% of these binding sites contained the canonical p53 motif, suggesting that p53 was either 
bound to degenerate recognition sites, in a sequence-independent manner, or through protein-
protein interactions (Fig. 49). The remaining peaks were distributed at distal intergenic locations 
and at gene bodies, where the p53-RE was more represented (Fig. 49). Peaks sitting on the 
consensus p53 motif showed higher p53 binding intensity compared to the ones where the p53-
RE was not identified (Fig. 50). 
 
Fig. 47 - Heatmaps of p53 binding sites in control and drug treated-Eμ-myc Arf
-/-
 Trp53
+/+ 
lymphomas. 
Heatmaps showing library size-normalized ChIP-seq read counts for all p53-bound promoters (-5/+2 kb 
from the TSS), gene bodies (+2 kb from the TSS through 3'UTR) and intergenic regions (everything else) 
at chromosome 1 in three Eμ-myc Arf
-/-
 Trp53
+/+ 
lymphomas cells (T) treated for 3 hr with 5µM (+)-
Nutlin, 5µM (-)-Nutlin, 0.1% H2O or 1µM doxorubicin, as indicated. Peaks are hierarchically clustered. 
The occurrence of the p53 motif at the genomic intervals analyzed is calculated by the FIMO algorithm 
(153) (p-value<1 x 10
-5
) and indicated with blue lines on the right side of the heatmaps. 
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Fig. 48 - Overlap of p53 binding sites in three Eμ-myc Arf
-/-
 Trp53
+/+
 lymphomas (T) treated with 5µM 
(-)-Nutlin or 1µM doxorubicin. 
Venn diagrams of p53 binding sites in three Eμ-myc Arf
-/-
 Trp53
+/+ 
lymphoma cells (T) treated for 3 hr 
with 5µM (-)-Nutlin or 1µM doxorubicin. Percentages indicate the number of peaks for each lymphoma 
present in at least another sample. 
 
Fig. 49 - Motif analysis and genomic distribution of p53-binding sites in Eμ-myc Arf
-/-
 Trp53
+/+ 
lymphomas following small molecules treatment. 
Characterization of all p53-bound sites at promoters (-5/+2 kb from the TSS, red bar), gene bodies (+2 
kb from the TSS through 3'UTR, green bar) and intergenic regions (everything else, blue bar) in three 
Eμ-myc Arf
-/-
 Trp53
+/+ 
lymphomas cells (T) treated for 3 hr with 5µM (+)-Nutlin, 5µM (-)-Nutlin, 0.1% 
H2O or 1µM doxorubicin, for the occurrence of the p53 motif as calculated by the FIMO algorithm (p-
value<1 x 10
-5
). The percentage of p53-bound sites containing the p53-RE is reported. 
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Fig. 50 - Stronger p53 binding sites are more likely to contain the consensus p53 motif. 
Peak enrichment of p53 binding sites that contain (grey boxes) or not (black boxes) the p53 motif in 
three Eμ-myc Arf
-/-
 Trp53
+/+ 
lymphomas cells (T) treated for 3 hr with 5µM (+)-Nutlin, 5µM (-)-Nutlin, 
0.1% H2O or 1µM doxorubicin. 
4.2.5 Genome-wide analysis of p53 binding during tumor suppression and regression 
Having established p53 binding patterns in control (C) and pre-tumoral Eμ-myc B cells (P) and with 
three modes of p53 restoration in tumors (T), we proceeded to compare these profiles. Both 
binding intensity and total number of p53 binding sites progressively increased from C and P to T 
(Fig. 51), consistent with the notion that the p53-dependent tumor suppressive response 
amplifies with increasing levels of oncogenic stress (132). In C and P, half of the p53 binding sites 
were at distal intergenic loci, and the remaining ones were equally distributed at promoters and 
gene bodies; the majority of the new p53 binding sites that appeared in tumors were instead 
located at promoter-proximal regions (Fig. 52). Most of these new p53 peaks at promoters didn't 
overlap with the p53 motif, suggesting that p53 was bound to weaker variant sites or recruited 
through protein-protein interactions (Fig. 51). Nevertheless, the specificity of all binding sites was 
supported by the fact that, when we considered all the peaks identified in each lymphoma model 
as a whole, we found that more than 80% of the peaks were present in at least two samples from 
different experimental models (Fig. 53). Upon p53 restoration in the Eμ-myc LSL-p53 lymphomas, 
we identified fewer peaks compared to the other lymphoma models and most of them were 
located at distal intergenic sites. In this experimental setting, our sensitivity in calling the peaks 
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was likely decreased by the incomplete recombination of the LSL cassette in the cell population 
and the quick outgrowth of undeleted clones. Moreover, the binding sites identified in the Eμ-myc 
LSL-p53 lymphomas were all present in the other samples, where they constituted some of the 
most enriched peaks, and almost all contained the p53 motif (Fig. 39). Therefore, the data 
produced in this experimental model helped in pointing out which where the high affinity sites in 
lymphomas upon p53 reactivation, leading to the observation that they were mainly distal sites. 
To characterize the binding sites identified, we checked for the presence of H3K4me3, H3K4me1 
and H3K27ac using our recently published ChIP-Seq data (157). The Eμ-myc lymphomas used in 
this study were different from the ones analyzed in this thesis except for the T1 in reference 
(157), which was labeled as T2 Eμ-myc Arf-/- Trp53+/+ lymphoma in this work. Since the location of 
these marks was substantially fixed in B cells and didn't change during tumor progression from C 
to P to T, we used them as reference to outline our p53 binding sites. These features marked all 
the p53-bound promoters, indicating that p53 localized at active regulatory regions. p53 binding 
sites with the chromatin signature characteristic of enhancers were similarly partitioned on intra-
and intergenic regions and constituted a noteworthy fraction of the distal sites (Fig. 54). The 
remaining distal sites, including a big portion of the high affinity sites bound by p53 in all 
lymphomas, didn't enrich for any of the chromatin features investigated, and hence remain to be 
characterized, although the presence of the p53-RE and the absence of these peaks in C and P 
excluded sequencing artifact. We also checked for the presence of RNA-Seq reads in the 
surrounding region but we didn't detect any significant enrichment; moreover, we overlapped 
them with the regulatory elements identified in B cells by Busslinger and co-workers (164), 
without observing any co-localization. In the future, we plan to search for the co-occurrence of 
different proteins at these sites using publicly available data. Finally, some distal sites bear the 
H3K4me3 mark, suggesting that they may instead represent the promoters of unannotated 
transcripts or ncRNAs.  
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Fig. 51 - Comparison of p53 binding profiles during tumor suppression and regression. 
Heatmaps showing library size-normalized ChIP-seq read counts for all p53-bound promoters (-5/+2 kb 
from the TSS), gene bodies (+2 kb from the TSS through 3'UTR) and intergenic regions (everything else) 
at chromosome 1 in C, P, three Eμ-myc LSL-p53 lymphomas and four Eμ-myc p53ER
TAM
 lymphomas 
upon 4-OHT treatment, and three Eμ-myc Arf
-/-
 Trp53
+/+
 treated with (-)-Nutlin or doxorubicin. Peaks 
are hierarchically clustered. The occurrence of the p53 motif at the genomic intervals analyzed is 
calculated by the FIMO algorithm (153) (p-value<1 x 10
-5
) and indicated with blue lines on the right side 
of the heatmaps. 
 
Fig. 52 - Genomic distribution of p53 binding sites. 
Percentages of p53 binding sites at promoters (-5/+2 kb from the TSS, red bar), gene bodies (+2 kb from 
the TSS through 3'UTR, green bar) and intergenic regions (everything else, blue bar). The reported 
values represent the average of three or four biological replicates. Error bars stand for standard 
deviation. 
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Fig. 53 - Identification of high-confidence p53 binding sites during tumor regression. 
Venn diagram of p53 binding sites identified upon p53 restoration in Eμ-myc LSL-p53 lymphomas, Eμ-
myc p53ER
TAM
 lymphomas, and Eμ-myc Arf
-/-
 Trp53
+/+
 treated with (-)-Nutlin or doxorubicin. Data shown 
for each condition represent the union of the p53 peaks identified in each lymphoma model. 
Percentages indicate the number of peaks shared with at least another model. 
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Fig. 54 - Distribution of p53 binding sites at annotated promoters and distal sites. 
Heatmaps showing the distribution of p53 at annotated promoters (panel A), distal intergenic sites 
(panel B) and at gene bodies (panel C) in C, P and T, as indicated. Each row represents a different 
genomic interval (4 kb width centred on p53 peaks). The panels include every annotated promoter and 
every distant location in chromosome 1 that is identified as p53-associated by ChIP-seq in at least one 
of the experimental samples. For the same intervals, the distributions of H3K4me3, H3K4me1, H3K27ac 
and annotated genes (exons in red, introns in pink; + sense, - antisense strand) are also shown (157). 
4.2.6 Expression profiling during tumor suppression and regression 
To identify genes important for suppression of cancer development, we used RNA-Seq to profile 
changes in mRNA levels during tumor progression and regression upon restoration of p53 
function. As described in our recent publication (157), the DEGs in Eμ-myc pre-tumor relative to 
control were mainly involved in metabolism, cell cycle and RNA processing, as expected from the 
comparison of mRNA levels in highly proliferating and less differentiated pre-tumoral B cells with 
86 
 
mature quiescent B cells. Thus, the transcriptional changes induced by p53 were confounded by 
the direct and indirect effects of Myc on gene expression. Moreover, it is most likely that the B 
cell population in pre-tumoral mice is a very heterogeneous population for p53 activation: at any 
time, only a small fraction of the cells may be experiencing oncogenic stress above the threshold 
required to activate the p53-driven apoptotic pathway (132), resulting in the dilution of the p53 
signal and therefore impacting on our sensitivity in detecting p53 binding sites and transcriptional 
response. Nevertheless, we could identify 13 genes, all up-regulated (except 4933426M11Rik), 
that had a p53 binding site at the promoter in the pre-tumoral sample (Table 8). The consensus 
p53 motif was found in the promoter-proximal region of all these genes, except Phlda3. A 
putative p53-RE was previously described overlapping the transcription initiation site of the 
Phlda3 gene (5'-GAACATGTAAGGGCACATCC-3') (165), but was not identified by our motif search 
due to the absence of a G in position 17, indicating that some bona fide p53-RE may be missed in 
our analysis due to the stringency of our statistical criteria. This list of genes included well-known 
p53 targets, such as Cdkn1a, Bbc3 and Ccng1, reinforcing its potential significance. Moreover, 
some of these genes were already validated tumor suppressors: both Cdkn1a and Bbc3 deficiency 
were shown to accelerate tumorigenesis in tumor-prone mouse models (104,106,107,108), while 
recently, Phlda3, the p53-regulated repressor of Akt, was demonstrated to increase tumor growth 
when knocked-down in allograft tumor assays (109,165). Finally, we identified three ribosomal 
proteins Rps27l, Rps19 and Rpl24. Myc-driven lymphomagenesis relies on protein biosynthesis 
and Rpl24 haploinsufficiency was demonstrated to delay Myc-induced tumor progression (166). 
p53 may create an imbalance in ribosomal protein production to trigger the checkpoint sensing 
the integrity of ribosome biogenesis. The remaining genes constitute new candidates for 
functional validation. 
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Table 8 - DEGs in Eμ-myc pre-tumor vs control bound by p53 at the promoter in P. 
Log2(FC) (log2 of fold-change) values of DEGs in Eμ-myc pre-tumoral B cells (P) vs control (C), that have 
p53 bound on the p53-RE at the promoter in P. 
To obtain a more comprehensive picture of the transcriptional programs induced by p53 
activation, we compared the expression changes triggered by different modes of p53 restoration 
in tumors. Activation of the p53ERTAM chimera by 4-OHT administration in Eμ-myc p53ERTAM 
lymphomas yielded approximately 800 DEGs, while around 1500 and 4500 DEGs were observed 
with (-)-Nutlin and doxorubicin treatment in Eμ-myc Arf-/- Trp53+/+ lymphomas, respectively. Upon 
p53ERTAM activation and (-)-Nutlin treatment, more than two-thirds of DEGs showed increased 
expression, while following doxorubicin treatment half of the DEGs were up-regulated and half 
down-regulated (Table 9). We observed that 65% of the genes induced upon p53 restoration in 
Eμ-myc p53ERTAM lymphomas also responded to both (-)-Nutlin and doxorubicin treatment in Eμ-
myc Arf-/- Trp53+/+ lymphomas and the remaining DEGs to doxorubicin treatment only; moreover, 
(-)-Nutlin-induced DEGs represented a fraction of the doxorubicin-induced ones (Fig. 55). The 
genes down-regulated by p53ERTAM restoration and (-)-Nutlin treatment were mainly different, 
with 20% and 10% in common, respectively, but they all constituted a fraction of doxorubicin-
repressed genes. Transcriptional changes induced in Eμ-myc p53ERTAM lymphomas by p53 
restoration were milder compared to the ones induced by drug treatment, with doxorubicin 
inducing the strongest changes (Fig. 56). Doxorubicin-induced transcriptional changes were 
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probably more intense because this small molecule triggered the DDR, which synergized with the 
Arf pathway to activate p53 (135). In line with this observation, Western blot analysis showed 
increased stabilization of p53 upon doxorubicin treatment compared to (-)-Nutlin treatment (Fig. 
45). Despite the difference in magnitude of the transcriptional changes induced by p53 
restoration in the various experimental models, they all followed consistent trends in the sense 
that we didn't identify genes down-regulated in one condition and up-regulated in the other. 
Since the transcriptional changes induced by (-)-Nutlin treatment and p53ERTAM activation were 
weaker, some of the doxorubicin-induced DEGs were missed in these two models, in which the 
increases in mRNA steady state levels were not sufficient to reach the threshold of statistical 
significance. In all instances, the highest transcriptional changes were associated to gene 
induction (Fig. 56). p53 ChIP-seq studies had shown that in cancer cells treated with different 
agents, total p53-binding profiles were remarkably similar despite significant transcriptional 
differences (80,158). Here, we observed well-overlapping p53 genome-wide maps upon p53 
restoration in different experimental settings (Fig. 51); however, also the gene expression changes 
were very homogeneous, consistent with the similarity in cell phenotypes observed. Smeenk et al. 
(80) and Nikulenkov et al. (158) instead used p53 activating drugs that resulted in either apoptosis 
or cell cycle arrest, revealing more substantial differences between DEGs. 
 
Table 9 - DEGs induced by three modes of p53 restoration in tumors. 
Summary of total numbers and percentages of induced and repressed genes in Eμ-myc p53ER
TAM
 
lymphomas following 4-OHT treatment, and in Eμ-myc Arf
-/-
 Trp53
+/+
 lymphomas following (-)-Nutlin 
and doxorubicin treatment relative to controls. 
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Fig. 55 - Comparison of genes that respond to p53 restoration in Myc-driven lymphomas. 
Venn diagram showing the overlap between the DEGs identified in Eμ-myc p53ER
TAM
 lymphomas 
following 4-OHT treatment, and in Eμ-myc Arf
-/-
 Trp53
+/+
 lymphomas following (-)-Nutlin and 
doxorubicin treatment relative to controls. 
 
Fig. 56 - Different modes of p53 restoration in lymphomas lead to similar transcriptional changes, 
despite differences in magnitude. 
Heatmap of the log2(FC) (log2 of fold-change) values of all up- and down-regulated genes (n=5055) 
upon p53 reactivation in Eμ-myc p53ER
TAM
 lymphomas following 4-OHT treatment, and in Eμ-myc Arf
-/-
 
Trp53
+/+
 lymphomas following (-)-Nutlin and doxorubicin treatment relative to controls. The genes are 
clustered hierarchically on the basis of their differential expression. 
To assess the p53 dependency of biological responses, we knocked down Trp53 in Eμ-myc Arf-/- 
Trp53+/+ lymphomas using a selectable retroviral vector expressing an shRNA against p53 (Fig. 57). 
Following (-)-Nutlin treatment, no DEG could be identified in lymphomas where p53 was silenced, 
indicating that the response measured was entirely p53-dependent (Fig. 58A). Doxorubicin 
treatment instead still caused significant regulation of 40 genes, and many more changed 
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transcripts levels even if not in a statistically significant manner and with smaller amplitude 
compared to wild-type cells. Thus, doxorubicin-induced changes were largely p53-dependent, but 
other factors contributed to the transcriptional regulation of most genes (Fig. 58B). The difference 
between the two p53-activating agents could probably be explained by the genotoxic effects of 
doxorubicin, which is not the case for (-)-Nutlin, and could then contribute to the expression 
changes via activation of DDR pathways.  
 
Fig. 57 - Efficiency of Trp53 knock-down. 
qPCR analysis of Trp53 mRNA levels in three Eμ-myc Arf
-/-
 Trp53
+/+
 lymphomas infected with a retroviral 
vector expressing an shRNA against p53 (shp53) and treated for 3 hr with 0.1% H2O, 1µM doxorubicin, 
5µM (+)-Nutlin or 5µM (-)-Nutlin, as indicated. Trp53 expression in one uninfected lymphoma was 
analyzed as positive control.  
 
Fig. 58 - p53 dependency of transcriptional changes. 
Scatter plot opposing the log2(FC) (log2 of fold-change) values of all DEGs as estimated by RNA-Seq 
analysis in Eμ-myc Arf
-/-
 Trp53
+/+
 lymphomas (not infected) following (-)-Nutlin (panel A) and 
doxorubicin treatment (panel B) relative to controls and the log2(FC) of the same genes in lymphoma 
cells infected with a retroviral vector expressing an shRNA against p53 (shp53). In case a gene is still 
differentially expressed in shp53 cells, it is marked with a blue dot.  
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4.2.7 p53-regulated transcriptional program during tumor regression 
To identify which of the differentially expressed genes induced by p53 restoration in lymphomas 
were direct p53 targets, we combined p53 binding with gene expression profiles. In all instances, 
approximately half of the DEGs, both up- and down-regulated, had at least one p53 binding site in 
the promoter proximal region (Fig. 59, Fig. 60). Approximately 20% of the p53-bound up-
regulated genes contained the p53 motif, which was instead less represented at the promoter of 
the repressed genes (Fig. 60), in line with what was previously observed in B and non-B cells from 
irradiated mice.  
 
Fig. 59 - Heatmap of all DEGs upon p53 restoration in Eμ-myc lymphomas together with the 
indication about enrichment of p53 binding at the corresponding promoter. 
Heatmap of the log2(FC) (log2 of fold-change) values of all DEGs (n=5055) as estimated by RNA-Seq 
analysis upon p53 restoration in Eμ-myc p53ER
TAM
 lymphomas following 4-OHT treatment, and in Eμ-
myc Arf
-/-
 Trp53
+/+
 lymphomas following (-)-Nutlin and doxorubicin treatment relative to controls, 
together with the indication about enrichment of p53 binding at the corresponding promoter (-
600/+400 bp from the TSS). 
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Fig. 60 - Absolute numbers of p53-bound DEGs. 
Bar plot showing the number of DEGs (total, up and down) divided as p53-bound, -unbound and -
bound on the p53-RE in Eμ-myc p53ER
TAM
 lymphomas following 4-OHT treatment, and in Eμ-myc Arf
-/-
 
Trp53
+/+
 lymphomas following (-)-Nutlin and doxorubicin treatment relative to controls, as indicated. 
Genes are considered bound if a p53 peak is identified nearby the TSS in at least one of the 
corresponding ChIP-Seq samples. 
To determine whether the presence of a p53 binding site was predictive of transcriptional 
activation of the corresponding gene, we determined the frequency of DEGs among the p53-
bound genes, distinguishing them between those containing or not the p53-RE. As in B and non-B 
cells upon acute DNA damage, p53 binding on the p53 motif in the promoter region of genes was 
more predictive of gene regulation compared to mere p53 binding (Fig. 61). Moreover, binding 
intensity of the p53 peaks containing the p53 consensus motif correlated with activation of the 
corresponding genes, and this linkage was not observed for the remaining p53-bound genes not 
overlapping with the canonical p53-RE (Fig. 62). The genes that were bound by p53 on the p53-RE 
and that didn't change expression, may be induced in a minor fraction of the cells, as indicated by 
the lower peak enrichment, and therefore their activation at the steady state level may not be 
detectable yet (Fig. 62). 
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Fig. 61 - Expression changes of p53-bound genes upon p53 restoration in Eμ-myc lymphomas. 
Bar plot showing the percentage and the absolute number of all p53 peaks and of p53 peaks containing 
the p53-RE at the promoters of genes in Eμ-myc p53ER
TAM
 lymphomas and in Eμ-myc Arf
-/-
 Trp53
+/+
 
lymphomas that don't change expression (black bar), or that are up-regulated (red bar) or down-
regulated (blue bar) following p53 restoration. 
 
Fig. 62 - Higher p53 binding intensities are most frequently correlated with transcriptional activation. 
Box plots showing the enrichment of p53 peaks in Eμ-myc p53ER
TAM
 lymphomas following 4-OHT 
treatment, in Eμ-myc Arf
-/-
 Trp53
+/+
 lymphomas following (-)-Nutlin and doxorubicin treatment at the 
promoter region of genes containing or not the p53-RE and that don't change expression (black box), or 
that are up-regulated (red box) or down-regulated (blue box) upon p53 reinstatement. The boxes are 
drawn with widths proportional to the square-roots of the number of observations in the groups. 
Results in lymphoma 1 for each experimental model are reported as representative of the other 
lymphomas. 
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A biological process GO analysis of the p53-bound genes containing the p53-RE indicated that 
they were involved in intracellular signal transduction, response to stress, apoptosis, negative 
regulation of growth and several other terms directly related to p53 activation. The remaining up-
regulated genes, whether bound or not by p53, enriched for categories related to regulation of 
gene expression and cell development. Finally, the down-regulated genes following (-)-Nutlin and 
doxorubicin treatment enriched for terms associated to cell cycle, cell division and RNA 
processing. Moreover, (-)-Nutlin-repressed genes were also linked to cholesterol biosynthesis, and 
the doxorubicin-down-regulated ones to cellular catabolic processes. The repressed genes upon 
p53ERTAM activation didn't enrich for any categories in a statistically significant manner. 
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Fig. 63 Functional annotation of all DEGs in Eμ-myc lymphomas upon p53 restoration. 
Gene Ontology terms enriched in up- and down-regulated genes upon p53 restoration in Eμ-myc 
p53ER
TAM
 lymphomas following 4-OHT treatment, and in Eμ-myc Arf
-/-
 Trp53
+/+
 lymphomas following (-)-
Nutlin and doxorubicin treatment relative to controls, further distinguished in p53-bound and unbound 
and containing the p53-RE. GO terms significantly enriched (Fisher test p-value<1*10
-5
) in at least one 
gene set are selected (rows in the heatmap) and the p-values for each GO term in each gene set 
(columns) are colour-coded as indicated. Only GO terms in the biological process ontology that are 
assigned to less than 2,000 and more than 10 genes in the mouse genome are considered.  
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Since the p53-bound genes containing the p53-RE were a minor fraction of all DEGs, we used IPA 
to try to identify the putative upstream regulators of the remaining DEGs. In doxorubicin-treated 
Eμ-myc Arf-/- Trp53+/+ lymphomas the down-regulated genes were involved in cell cycle and 
mitosis, as in B and non-B cells exposed to acute DNA damage; therefore, IPA indicated as 
putative upstream regulators of these genes the let-7 microRNA and the p21/Rb/E2f pathway 
(Table 10). For the down-regulated genes upon p53ERTAM activation the p-value associated to the 
putative regulators identified were higher, due to the smaller number of DEGs analyzed, making 
the results more uncertain. Finally, among the putative regulators of the down-regulated genes 
upon (-)-Nutlin treatment, we noticed SREBF1 and 2. The SREBF transcription factors were 
described to cooperate with mutant p53 to induce the genes involved in sterol biosynthesis, 
contributing to the malignant phenotype in breast cancer cells (167). Here, we found indications 
that wild-type p53 could have the opposite effect of dampening the expression of SREBF target 
genes. 
 
Table 10 - Putative upstream regulators of down-regulated genes upon p53 restoration in Eμ-myc 
lymphomas. 
IPA Upstream Regulator Analysis of down-regulated genes having or not a p53 binding site at the 
promoter containing the p53-RE in Eμ-myc p53ER
TAM
 lymphomas following 4-OHT treatment, and in Eμ-
myc Arf
-/-
 Trp53
+/+
 lymphomas following (-)-Nutlin and doxorubicin treatment relative to controls. 
Statistical significance and p-values are determined by IPA using a Fisher's Exact Test.  
As expected, p53 and its family members p63 and p73 were indicated as the most probable 
regulators of the p53-bound genes containing the p53-RE. For the remaining up-regulated genes, 
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IPA results were less clear: we couldn't identify any putative regulator in common between the 
different modes of p53 reactivation in tumors and none of the ones highlighted was a direct p53 
target. However, even if not highlighted by IPA, among the p53 target genes containing the p53-
RE we identified the transcription regulators Foxo3, Notch1, Fos (that dimerizes with Jun to form 
the AP-1 complex), and several zinc finger proteins (73,168,169). In the literature, there are 
already indications that Foxo3 plays a role in p53-dependent apoptosis (168,170), while AP-1 and 
Notch1 are known to control several processes, including cell proliferation and death, and may 
thus conceivably contribute to gene regulation downstream of p53. 
 
Table 11 - Putative upstream regulators of up-regulated genes upon p53 restoration in Eμ-myc 
lymphomas. 
IPA Upstream Regulator Analysis of up-regulated genes having or not a p53 binding site at the 
promoter containing the p53-RE in Eμ-myc p53ER
TAM
 lymphomas following 4-OHT treatment, and in Eμ-
myc Arf
-/-
 Trp53
+/+
 lymphomas following (-)-Nutlin and doxorubicin treatment relative to controls. 
Statistical significance and p-values are determined by IPA using a Fisher's Exact Test.  
4.2.8 Comparison between the response of B and non-B cells to genotoxic stress and of Eμ-
myc lymphoma cells to p53 restoration 
In the previous paragraphs, we described the response of B and non-B cells to IR and of Eμ-myc 
lymphoma cells to p53 restoration. In both experimental settings, we characterized p53 binding 
sites and identified a p53-dependent program, both directly and indirectly regulated by p53. 
Initially, we proceeded to compare p53 binding patterns: all p53 binding sites identified in Eμ-myc 
lymphoma cells were also present in wild-type B and non-B cells upon IR (Fig. 64). p53 binding 
sites progressively increased from C to P to T to the irradiated samples, initially occupying 
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prevalently high affinity p53-REs and then progressively spreading to new sites not containing the 
p53 motif. 
 
Fig. 64 - Comparison of p53 binding profiles during tumor suppression, regression and in response to 
acute DNA damage. 
Heatmaps showing library size-normalized ChIP-seq read counts for all p53-bound promoters (-5/+2 kb 
from the TSS), gene bodies (+2 kb from the TSS through 3'UTR) and intergenic regions (everything else) 
at chromosome 1 in C, P, Eμ-myc LSL-p53 lymphomas and Eμ-myc p53ER
TAM
 lymphomas upon 4-OHT 
treatment, Eμ-myc Arf
-/-
 Trp53
+/+
 upon (-)-Nutlin or doxorubicin treatment, B and non-B cells from 
irradiated animals. Peaks are hierarchically clustered. The occurrence of the p53 motif at the genomic 
intervals analyzed is calculated by the FIMO algorithm (153) (p-value<1 x 10
-5
) and indicated with blue 
lines on the right side of the heatmaps. 
We previously described that the transcriptional response to p53 restoration in Eμ-myc 
lymphomas was very similar in the various models, despite differences in the magnitude of 
expression changes (Fig. 56). B and non-B cells response to IR was instead for a large part cell 
type-specific with many genes that preferentially responded in one cell type or the other, except 
for the p53-activated program that constituted the gene set with the highest percentage of 
common DEGs between B and non-B cells (Fig. 14, Table 2). When we looked at the whole 
transcriptional response in B and non-B cells following IR and compared it with the expression 
changes observed upon p53 restoration in Eμ-myc lymphoma cells, we noted a group of genes 
that was strongly up-regulated in all conditions, few genes that moved in opposite directions in 
lymphomas compared to wild-type cells and many genes that responded in one condition but not 
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in the other (Fig. 65A). When we removed the p53-independent DEGs from the analysis, we noted 
a group of genes involved in the response to DNA damage that was up-regulated independently of 
the cellular context and the upstream stress signal, genes involved in cell adhesion and migration 
specifically induced following ionizing radiation, while the most repressed genes were implicated 
in cell cycle and mitosis (Fig. 65B). 
 
Fig. 65 - All DEGs upon different modes of p53 activation. 
Heatmap of relative levels of total mRNA for all DEGs (panel A, n=8598) and all p53-dependent DEGs 
(panel B, n=7036) upon p53 reactivation in Eμ-myc p53ER
TAM
 lymphomas following 4-OHT treatment, in 
Eμ-myc Arf
-/-
 Trp53
+/+
 lymphomas following (-)-Nutlin and doxorubicin treatment, and in B and non-B 
cells following IR relative to controls. The genes are clustered hierarchically on the basis of their 
differential expression. Biological process GO terms with p-values as calculated by DAVID (154,155) 
using a modified Fisher exact test are reported. 
To explore the directly regulated p53 response, we compared the p53-dependent DEGs that were 
bound by p53 on the p53-RE in the different experimental models and identified 23 genes that 
were induced independently of the activating stress and of the cell type, representing the 'default 
p53 program' (Fig. 66) (158). This list included genes involved in apoptosis, such as Aen, Pmaip1, 
Bbc3 and Lrdd, cell cycle regulators, such as Cdkn1a and Ccng1, the negative regulator of p53 
Mdm2, and several novel p53 target genes. Other genes preferentially responded to one 
condition and not the other, likely representing stress-specific effectors of the p53 response. All 
these genes constitute strong candidates to mediate tumor suppression.  
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Fig. 66 - Heatmap of all p53-dependent DEGs that are bound by p53 on the p53-RE in Eμ-myc 
lymphomas upon p53 restoration and in B and non-B cells following IR. 
Heatmap of the log2(FC) (log2 of fold-change) values of all DEGs (n=333) as estimated by RNA-Seq 
analysis upon p53 restoration in Eμ-myc p53ER
TAM
 lymphomas following 4-OHT treatment, in Eμ-myc 
Arf
-/-
 Trp53
+/+
 lymphomas following (-)-Nutlin or doxorubicin treatment, and in B and non-B cells 
following IR relative to controls. The genes identified as direct p53 targets in all experimental models 
are reported. 
Currently, we are testing the impact of some of these p53 target genes on tumorigenesis with a 
shRNA screen in vivo, following the protocol established in the Lowe's lab (171) (Fig. 67). We 
selected genes that were not previously described as tumor suppressors, prioritizing the ones that 
were activated in our tumor progression and regression models. We designed an shRNA library 
using on-chip oligonucleotide synthesis and a barcoding strategy such that the shRNAs could be 
amplified from the mixture in pools of 55 shRNAs targeting 11 genes (5 shRNAs per gene) for a 
total of 30 pools. Pre-malignant hematopoietic stem and progenitor cells (HSPCs) from Eμ-myc 
fetal livers ED 12.5-14.5 will be infected with the pools and transplanted in sub-lethally irradiated 
recipient mice to screen for their ability to increase the lymphomagenic potential. We tested 
serial dilutions of cells transduced with a green fluorescent protein (GFP)-coupled shRNA against 
p53 and observed that 2000 transduced cells diluted with uninfected cells were sufficient to 
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accelerate lymphomagenesis and the resulting lymphomas were GFP positive (Fig. 68). By 
contrast, a control GFP-tagged scrambled shRNA did not accelerate lymphomagenesis. Once the 
mice will develop lymphomas, we will extract the DNA, PCR-amplify to isolate the shRNAs and 
sequence on the Illumina platform. shRNAs that will be kept in the tumor are candidate tumor 
suppressors and will be subsequently validated. The screening is currently ongoing and hopefully 
will identify new tumor suppressor genes, paving the way for their therapeutic application. 
 
Fig. 67 - Functional screening of candidate gene set in vivo. 
Pre-malignant hematopoietic stem and progenitor cells from Eμ-myc transgenic mice are infected with 
pools of shRNAs targeting candidate tumor suppressor genes and transplanted in sub-lethally irradiated 
recipient mice. The DNA from the resulting lymphomas is PCR-amplified to isolate the shRNAs and 
sequenced.  
 
Fig. 68 - Setup of the experimental conditions for functional screening of candidate tumor suppressor 
genes in vivo. 
Survival curves of mice transplanted with HSPCs infected with a neutral shRNA (scrambled, black, n=7), 
shp53 (p53, red, n=5), or diluted shp53 in order to tail vein inject only 2000 GFP-positive cells (p53 
2000, orange, n=9). 
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5 Discussion 
The genetic programs used by the p53 tumor suppressor to direct stress-specific biological 
responses remain to be clarified. Here, to gain novel insights into p53 function, we combined 
whole genome mapping of p53 binding and gene expression profiling to investigate the 
transcriptional circuitry employed by p53 in suppressing cancer development and in response to 
DNA damage. We studied the progression of Myc-induced lymphomas in Eμ-myc transgenic mice, 
as well as the regression of these lymphomas following restoration of p53 function, by either 
pharmacological or genetic means. In parallel, we determined the p53-dependent transcriptional 
program in splenic B and non-B cells of mice exposed to acute DNA damage. Our study revealed 
novel components of the p53-regulated network and indications of the regulatory mechanisms 
downstream of p53 activation. 
5.1.1 p53 was bound to DNA in unstressed conditions 
p53 was already bound to chromatin in unstressed cells, as observed in non-transgenic control 
mice (C) of the Eμ-myc colony and in non-irradiated C57/Bl6 mice. The binding of p53 to 
chromatin under basal conditions was previously reported in primary cells grown in vitro 
(64,69,78), but culture-associated stress may have constituted an activating stimulus; only 
recently p53 was shown to play a role under physiological conditions in vivo in developing kidney 
(83). Our data therefore confirmed that p53 was bound to DNA in the absence of any extrinsic 
stress in vivo and suggested that p53 was likely poised for activation at its response elements to 
provide a fast response to stress, as it had been previously shown for Cdkn1a (172,173). It is 
noteworthy that few p53-binding sites were detected in these conditions, implying that (i.) p53 
was present at very low levels and/or (ii.) it was activated in a minority of the cells at any given 
time. Furthermore, not all of the genes bound by p53 in control conditions became differentially 
expressed in response to stress, implying a two-stage mechanism whereby p53 binding should be 
followed by a second layer of regulation, such as the recruitment of cofactors or PTMs, to result in 
differential expression. For example, acetylation of the DNA binding domain of p53 was shown to 
play a key role in modulating the expression of p53 target genes, and mutation of the modified 
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residues completely impaired p53's ability to induce apoptosis, cell cycle arrest and senescence in 
MEFs (111). Similarly, phosphorylation of p53 at Serine 46 has been proposed to be required for 
the expression of apoptotic genes (80). Numerous cofactors have been described that can modify 
the p53 transcriptional program: these binding partners can function either by altering p53 target 
gene selectivity, or by affecting the ability of p53 to recruit transcriptional co-activators at certain 
loci (32). The distribution of p53 modifications and cofactors in Myc-induced lymphomas remain 
to be addressed, and will add an additional layer of information to the data described here. 
5.1.2 p53 was bound to a common set of sites irrespective of the type of stimulus and the 
cellular context 
We observed that p53 was bound to the same sites in B cells from control (C) and Eμ-myc pre-
tumoral mice (P), yet, with higher intensity in the latter. It is most likely that B cells in pre-tumoral 
mice are a very heterogeneous population for p53 activation: at any time, only a small fraction of 
the cells may be experiencing oncogenic stress above the threshold required to activate the p53-
driven apoptotic pathway (132) and this fraction increases from C to P. Nevertheless, this results 
in the dilution of the p53 signal, impacting on our sensitivity in detecting p53 binding sites. The 
number and the binding intensity of p53 peaks increased in tumors in which p53 was 
experimentally re-activated (T), consistent with the notion that the p53 response amplifies with 
increasing levels of oncogenic stress (132). The overall p53 binding profiles in the various T 
samples were very similar, even if we used very different modes to restore p53 function, such as 
genetic activation, inhibition of Mdm2 with (-)-Nutlin and doxorubicin-induced genotoxic stress. 
Moreover, almost all of the binding sites in T were retrieved in wild-type B and non-B cells 
following IR, supporting the hypothesis previously raised by others of a 'default set' of p53 binding 
sites not influenced by the activating stimulus or the cellular context (67,80,158). On the other 
hand, these data contradicted a previous study, which observed that p53 in normal cells (IMR90 
fibroblasts), was recruited to genomic locations that were significantly different from those 
occupied in transformed cells (HCT116 colorectal cancer cell and U2OS osteosarcoma cells) (82), 
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albeit it should be noted that those normal and transformed lines originated from totally different 
tissues.  
Most p53 peaks in C and P contained the canonical p53 motif; the same was observed in Eμ-myc 
LSL-p53 lymphomas where we could identify only the high affinity sites because our sensitivity in 
detecting p53 binding was affected by the incomplete recombination of the LSL casette. In the 
remaining tumor samples, as in B and non-B cells following IR, the number of binding sites 
increased and the p53-RE was less represented. Altogether these ChIP-seq data suggested that 
endogenous p53 was initially bound to high affinity sites, characterized by the presence of the 
p53 motif, and then progressively spread to weaker variant sites through DNA scanning or 
interaction with other DNA binding proteins. 
5.1.3 p53 was bound to many distal loci. 
In all conditions tested, we observed the presence of p53 binding sites at distant loci. In C, P and 
Eμ-myc LSL-p53 lymphomas, the majority of p53 peaks was located at distal sites, indicating that a 
large fraction of high affinity p53 sites was not in the promoter-proximal region. A portion of 
these p53 peaks showed the characteristic features of enhancers (high H3K4me1 and low 
H3K4me3). Enhancers have been shown to play a central role in p53-mediated gene regulation: 
on one hand, p53 was described to interfere with enhancer activity to repress the expression of 
target genes in mESC (78); on the other, it was shown to induce the expression of enhancer RNA 
to activate target genes in fibroblasts (79). In support of an activating rather than a repressing role 
of p53 at enhancers, Espinosa and co-workers described the transcription of eRNA from proximal 
sites (<25 kb from a gene) associated with direct p53-induced genes (86). A more extensive 
characterization of the role played by p53 at enhancers would advance our understanding of the 
regulatory mechanisms employed by p53 to regulate tumor suppression: however, this would 
entail a precise assignment of the enhancers elements identified in B cells to specific genes, 
through long-range association studies, which is currently being pursued in our group through 
dedicated collaborations.  
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Finally, it is noteworthy that not all distant p53 binding sites showed the characteristic chromatin 
signature of enhancers: we also identified strong p53 peaks in regions devoid of H3K4me3, 
H3K4me1, or H3K27ac. These sites were high affinity sites, as supported by the identification of 
the consensus p53 motif, but neither overlapped with previously characterized regulatory regions 
in B cells (164), nor enriched for RNA-Seq reads. The role played by p53 at these sites is still under 
investigation: in particular, we hope to obtain some clues by searching for the co-occurrence of 
other proteins in B cells or other cell types. 
5.1.4 p53 binding on the p53-RE nearby the TSS of a gene was predictive of p53-dependent 
gene regulation.  
p53 binding on the p53 motif was systematically present only at the promoters of p53-dependent 
genes; however, only a fraction of these p53-bound genes was differentially regulated in response 
to stress. These genes may not be clearly regulated at the time point investigated or require the 
recruitment of specific cofactors or PTMs for a complete activation. 
The observation that p53 binding on the p53-RE nearby the TSS of a gene was predictive of p53-
dependent gene regulation, may sound very obvious as the presence of the p53 protein on its RE 
has been traditionally used as a criteria to define p53 target genes (63). However, these 
distinctions became evident only upon analysis of ChIP-Seq data with enough sequencing depth, 
leading to the accurate detection of low-intensity peaks not associated to the canonical p53 motif. 
For example, without this distinction, we would have missed that p53-mediated repression was 
likely indirect (discussed below) and that the strongest binding was coupled with the activation of 
gene expression. In the future, we plan to relax the stringency in searching the p53 motif to study 
how non-canonical or slightly variant sequences contribute to the p53 response. Binding affinity 
could allow for a fine-tuning of the response through the regulation of p53 protein levels: for 
example, it has been shown that the choice between regulating cell cycle arrest and apoptosis is 
dictated by the presence of high and low affinity sites at the promoter of target genes, 
respectively (67). 
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5.1.5 p53-regulated gene network 
Combining ChIP-Seq and RNA-Seq analysis, we identified a set of genes directly and indirectly 
regulated by p53 in Eμ-myc lymphomas upon p53 restoration through genetic activation of 
p53ERTAM, doxorubicin or (-)-Nutlin treatment, and in B and non-B cells following IR. A minor 
fraction of the p53-dependent genes was bound by p53 on the p53-RE, thus likely representing 
direct p53 targets; among them, some were induced independently of the activating stress and of 
the cell type, thereby constituting the 'default p53 program'. However, since most of the p53-
dependent response was indirectly regulated, other transcription factors, under direct control of 
p53, should cooperate to expand the regulatory network. We identified transcriptional regulators, 
such as Foxo3, Notch1, Fos and several zinc finger proteins that were directly regulated by p53 in 
Eμ-myc lymphomas. FoxO3 belongs to a family of transcription factors involved in longevity and 
tumor suppression (174,175) and was shown to control the expression of genes involved in 
apoptosis, cell cycle arrest and DNA repair, including known p53 target genes (174,176). 
Moreover, FoxO3 itself was described as a p53 target (168). Finally, abrogation of FoxO function 
using a dominant-negative form of FoxO factors accelerated Myc-driven lymphomagenesis by 
blocking p53-dependent apoptosis (170). All these evidences suggest that FoxO3 and p53 likely 
cooperate to achieve tumor suppression. Fos and Notch1 are also known p53 targets (73,169), 
however less is known about their possible involvement as mediator of the p53 response. 
Therefore, it would be extremely interesting to characterize if and how FoxO3, Fos and Notch1 
contribute to the p53-activated programs in our experimental models. The regulation of p53-
dependent genes not directly bound by p53 at the promoter level could be otherwise achieved 
through enhancers, as previously discussed.  
5.1.6 p53-mediated gene repression was largely indirect.  
While the role of p53 as a transcriptional activator has been extensively studied, how p53 
represses transcription is still a matter of debate. The different modes of p53-dependent 
transcriptional repression described so far can be grouped in direct (DNA binding-dependent) and 
indirect (DNA binding-independent) mechanisms. The first ones have been proposed to include 
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either displacement by p53 of specific activators from promoters due to the presence of 
overlapping binding sites, interference of p53 with distal enhancer elements, the binding of p53 
to unique “repression” response elements, or recruitment by p53 of chromatin-modifying factors, 
such as histone deacetylases, which then block gene expression (35,78). Our data indicated that 
repression induced through p53 binding on the p53-RE is not a major component of the global 
p53 transcriptional program. 
p53 may also suppress transcription indirectly by regulating the expression of microRNAs and long 
non-coding RNAs (177). Our analysis indicated that gene repression of cell cycle and mitosis genes 
was likely mediated by transactivated gene products such as microRNAs and Cdkn1a/p21, which 
inhibited Cdks, resulting in Rb hypophosphorylation and repression of E2f targets. Moreover, the 
repression of genes involved in sterol biosynthesis was likely achieved through the impairment of 
the transcription factors SREBF1 and 2, which were shown to cooperate with mutant p53 to 
activate the expression of the mevalonate pathway genes, leading to a more invasive and 
malignant phenotype in breast cancer cells (167). This observation could represent another 
example of mutant and wild-type p53 opposing functions.  
5.1.7 Identification of new putative tumor suppressor genes.  
Targeting p53 for tumor eradication is not always possible, therefore the identification of p53 
targets that could be activated to restore p53 tumor suppressive function in tumors constitutes a 
promising new route for cancer therapy. Here, we identified a set of novel p53 target genes that 
are strong candidates for mediating tumor suppression. A valuable tool to test if these new 
components of the p53 transcriptional program are important to prevent tumor development is 
provided by functional genetic screens. RNAi-based experimental tools allow stable gene silencing 
and can be exploited to mimic gene loss during tumorigenesis in mice, leading to the 
identification of genes whose knock-down can promote cancer development. We decided to carry 
out a large scale, phenotype-based screen to examine the consequences of depleting some of the 
genes we identified on lymphomagenesis. These tools have been already successfully applied to 
test the impact of silencing candidate tumor suppressors on tumorigenesis (171). Hopefully, this 
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functional genetic screen will highlight new cancer preventing genes, paving the way for their 
therapeutic application. 
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